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To establish a predictive human infected in vitro system for Cystic fibrosis (CF) lung 
infection, we set-up a P. aeruginosa-infected model at the air-liquid interface (ALI), 
constituted by the human cystic fibrosis bronchial epithelial cells (CFBE41o-) in the apical 
side of a transwell and human macrophages (THP-1) in the basolateral side.  
Planktonic P. aeruginosa infection of CFBE41o- cells led to an earlier biofilm 
formation after 6 hours. Macrophages migrated towards the infection side, on the apical 
compartment already after 3 hours of infection, and were able to internalize the bacteria. 
Upon tobramycin treatment, the bacterial killing was higher on an abiotic surface (plastic 
plates) than on cell surface, which suggests an overestimation of the drug efficacy in cell-free 
assays. 
            Perspectively, this model can be used to further investigate the immune system. Here, 
we present the characterization of a neutrophil-like cell, HL-60, and its potential to be a 
platform to use neutrophils as delivery methods of internalized nanoparticle therapy. Aiming 
for therapy, we assessed the potential of quaternary ammonium surfactant-liposomes to 
inhibit bacterial adherence. That was the first step to develop a particle to simultaneously 




Um ein prediktives infiziertes humanes in-vitro System für eine Lungeninfektion im 
Rahmen einer ZF zu etablieren, haben wir ein mit P. aeruginosa infiziertes Modell, welches 
über eine Grenzfläche Luft/Flüssigkeit verfügt, erstellt. Dieses Modell besteht aus humanen 
zystisch-fibrotischen Bronchalepithelzellen (CFBE41o-) auf der apikalen Seite und humanen 
Makrophagen (THP-1) auf der basolateralen Seite.  
Die Infektion von CFBE41o- Zellen mit planktonischen P. aeruginosa führte nach 6 
Stunden zu einer früheren Biofilmentwicklung. Makrophagen migrierten bereits nach 3 
Stunden zur infizierten Seite und waren, Bakterien in sich aufzunehmen. Bei der Behandlung 
mit Tobramycin fand eine stärkere Abtötung auf einer abiotischen Oberfläche statt als auf 
einer Zelloberfläche, was eine Überschätzung der Wirkstoffeffektivität bei zellfreien Tests 
nahelegt.  
Hierbei stellen wir die Charakterisierung einer Neutrophilen-ähnlichen Zelle, HL-60, 
vor sowie deren Potential als Platform zu dienen, an dem Arzneistofftransportmethoden der 
internalisierten Nanopartikeltherapie getestet werden können. Wir  haben die Fähigkeit von 
quartäre oberflächenaktive Ammoniumverbindung-Liposomen, bakerielle Anhaftung zu 
verhindern, untersucht. Dies war der erste Schritt bei der Entwicklung eines Partikels, das die 
Adhäsion hemmt und gleichzeitig dazu dienen kann, mit Antibiotika - im Sinne eines 




Chapter 1: Establishment of CFBE41o- and THP-1 infected co-culture 
1. Introduction 
1.1. Respiratory system 
The respiratory tree branches out into several bifurcations directly from the trachea. 
Although the trachea does not take part in gas exchange, it is from the trachea that the 
bronchi start with two branches that are followed by the bronchial and bronchiolar 
bifurcations. Those branches will progressively decrease to give rise to peripheral branches 
and the alveolar region. In there, the alveoli are the main stations responsible for the gas 
exchange.1 
The lung and the respiratory branches are protected by an epithelial barrier that has 
important roles like i) avoids insults, ii) can self-repair and modulate airways response, and 
iii) release defensive fluids as the mucus, surfactant and lining fluid that contains 
antimicrobial peptides.2  
Among the epithelial cells, fifty cell types compose the respiratory system with 
unique functions, according to its location. The lower airways include the bronchial region, 
and it is composed by a pseudo-stratified epithelium of columnar cell to secretory goblet 
cells, basal and ciliated cells that are important on the mucociliary clearance mechanism; 
while cuboid and Clara cells are the ones located at the terminal bronchioles. The deep lung 
or distal airways are composed of type I and II alveolar cells. Moreover, macrophages are the 
first-encounter immune cells that can be located on top of the alveolar epithelium or in 
between the layers of the bronchial airways as interstitial macrophages.3 
1.1.1. Airways epithelium 
The airway epithelium is the main biological barrier of the lung and is responsible for 
the strategies around mucociliary clearance, the maintenance of levels in ion content and 
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surface fluid, plus the release of mucus containing anti-inflammatory, antiinfectives and 
antioxidant defenses.4  
However, the airway cellular structure provides a line of defense itself that is 
promoted by cell-to-cell connections as a barrier (Figure 1). When this barrier faces 
challenges, like the exposure to allergens or microbes, it becomes compromised, resulting in 
cytotoxicity and inflammation5.  
 
Figure 1. Light micrographs of bronchial airways histology. A) Low magnification of the bronchial wall for 
orientation. B) bronchial mucosa showing the ciliated cells, rare goblet cells, and basal bronchial cells resting on 
a thin basement membrane. Adapted with permission from 6. 
 
The integrity of the epithelial barrier is promoted by the tight junctions proteins 
(claudins, occludin, zona occludens-1, E-cadherins), and it separates the transport of 
molecules, particles, and other cells in compartments: the apical and basolateral7. These 
proteins are master regulators of the molecules’ flow, including the maintenance of the 
surface lining fluid and the release of antimicrobial molecules. The epithelial barrier is also 
the entrance point of control for inhaled microbes towards the bloodstream, so its integrity is 
a demanded line of defense.8 
 Alterations as cell damage, cell lesions, loss of permeability, cell reprogramming are 
main consequences from pathological modifications caused by diseases as lung cancer, 
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COPD, or cystic fibrosis.9 Such alterations can be either triggered or worsened by the 
inhalation of particulates as environmental pollutants and microbes10.  
 The above mentioned-lung alterations raise the need for suitable models in which such 
modifications could be emulated. For instance, the development of the model towards the 
features of how regeneration, pathology, lung exacerbation, and therapeutics pose the 
strategies to avoid or treat insults to the lung. While animal models have significantly been 
used to study CF disease, they fail to reproduce the spontaneous CF lung disease, most likely 
due to inter-species differences 11,12.  
1.1.2. Models of the human lung  
To be instrumental for the comprehension of alterations during the developed or 
diseased lung, animal models are a valid option. When functional studies were performed 
towards molecular lung alterations, animal models present a different outcome when 
comparing genetic gain- and loss-of-function, mostly due to differences as i) fast 
development of the mouse lung with increased branching of the airways tree before the actual 
development of the alveoli, ii) development of alveoli only post-birth and iii) residence of 
progenitor cells different to humans. These, among others, represent a failure in 
recapitulating the human lung.13  
When mimicking disease, lung injuries on rodents can trigger fibrosis and 
emphysema, an advantage for uncovering the complex mechanisms of these diseases14. Also, 
entire processes involving the physiology of branch morphogenesis can be studied with the 
mice arborized tree15. Nonetheless, on preclinical tests using animal models, most new 
molecules are effective, and about 80% of the approved molecules end up as false positives 
when translated to human clinical trials16. Therefore suitable human in vitro models are 
needed for a better prediction of drug efficacy. Moreover, in vitro models can provide 
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screening platforms of large-scale, assessment of specific cell-to-cell molecular differences 
and the opportunities to understand lung disorders while, at the same time, offer personalized 
medicine13. 
Ex vivo models are remarkably useful in the sense that one uses part of the whole 
lung, in which it can be reconnected for artificial input (drugs, particles, pathogens) to 
increase the model complexity; alternatively, slices of the lung can be cultivated17. These 
approaches preserve not only the in vivo architecture but also the cell types enclosed to it. In 
fact, models as the embryonic chicken trachea had shown independent of particle size or 
shape, the activity of mucociliary clearance is still effective. Alternatively, models as the 
porcine lung show a spatial availability very close to the human lung. 18 
Sakagami17 reviewed different lung models towards the testing of inhaled drugs and 
addresses the choice of model is intrinsic to the scientific question. On the modeling of 
complex interaction from a living organism, the in vivo model will provide the level of 
complexity; however, to address the lung barrier or cell interaction with other cells or 
particles or pathogens the in vitro model might be a better choice for studying this interplay. 
Direct cultivation of cells from the trachea, bronchi, and alveoli is possible with the 
advances in cell culture and the access to primary cells. However, the approximate cultivation 
of primary cells needs to mimic the lung environment, including the air-to-lung interface19. In 
fact, the use of cultures at the air-liquid interface (ALI) on permeable membranes is a valid 
and commonly used method in respiratory research. This is validated with the profiling of 
mRNA expression of cultures in ALI versus direct human airways derived from 
bronchoscopy or bronchial brushing.19  
From the sampling of human lungs, recent progress has allowed the expansion of 
patient-specific cells on the development of inducible pluripotent stem cells (iPSC)20. This 
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cellular model brings the opportunity for a full genetic background related to disease, in 
which personalized medicine and research on gene targets and repair can be used, including 
mutations derived from cystic fibrosis.21 Nonetheless, to create iPSC, one needs a batch of 
samples obtained from different patients and this individuality could result in increased 
differences regarding age, sex, disease severity and other pathophysiological variables.22 
By providing a three-dimensional environment, cells will take this as biological cues 
to behave as an in vivo scenario, including in modes of self-assembly. For that, bronchial 
cells, lung fibroblasts or endothelial cells can be cultivated as airway organoids.23 3D models 
can, for instance, i) make use of extracellular matrix, ii) generate bronchospheres, and ii) 
establish bronchial cells with fibroblasts to stimulate plasticity with proximal cell interaction 
and microenvironment of a co-culture. This evolution is represented in fig. 2 from 
monolayers to the use of microfluidic chips to show influence of shear stress. 
 
Figure 2. Evolution of in vitro models of the human lung. Adapted with permission from 13. 
Although primary cell culture is available, it is more demanding and expensive than 
expected, so, the use of immortalized cell lines has prevailed. Those cells derived from well-
defined diseases or from specific parts of the lung bring the stability of infinite proliferation 
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with the advantages to preserve cell morphology and functionality. Some of the most recent 
models recapitulate the lung with cell lines or the combination of those, as shown in figure 3. 
Figure 3. Lung constructs of the human bronchial epithelium. Calu-3: human airway epithelial cells, 
representative of airway submucosal glands; 16HBE14o−: human bronchial epithelial cell line; NHBE: primary 
human bronchial epithelial cells; BEAS-2B: human bronchial epithelial cell line. Reproduced with permission 
from 3 
 
On a transwell system or on a chip, advanced models as co-cultures have successfully 
mimicked the interaction of lung cells, as shown in figure 4. The airway epithelium, 
bronchial or alveolar, is always present as the main barrier, which can be complemented by 
other cellular components like immune cells. To mention a few, the combination of bronchial 
cells/fibroblasts, endothelia/eosinophils, bronchial cells/alveolar macrophages is already 
reported. Even commercialized models as MucilAir™ with immune cells can provide the 
reliability to understand pathology, inflammation, and host response (as for instance, 














Figure 4. Examples and applications of advanced lung co-culture models. A549: human alveolar type II cell; MDM: human blood monocyte-derived macrophages; MDDC: 
human blood monocyte-derived dendritic cells; 16HBE14o−: human bronchial epithelial cell line; HUVEC: human umbilical vein endothelial cells; Wi-38: human lung 
fibroblast cells line; NCI-H441: human lung adenocarcinoma cell line; HPMEC: primary human pulmonary microvascular endothelial cells; ISO-HAS-1: human 
hemangiosarcoma cell line, HBECs: primary human bronchial epithelial cells; Calu-3: human airway epithelial cells, representative of airway submucosal glands; HFL-1: 
human fetal lung fibroblasts; EA.hy 926: human umbilical vein cells; THP1: human monocytic cell line; HMC-1: human mast cell line; E10: nontumorigenic alveolar type II 
cells; HMVEC-L: human pulmonary microvascular endothelial cells.25 
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From the efficiency of particle/drug delivery to the toxicity of this material, a triple 
co-culture of alveoli, macrophages, and dendritic cells provide better information on 
toxicological reactions to therapy.26 The access to cells can be mimicked on co-cultures 
producing an alveolar-capillary barrier and acknowledging the intensity of toxicity derived 
from materials as silica nanoparticles.27 
 On that note, the access of nanoparticle formulation can take a different view, since 
the co-culture cell interaction can show an increased expression of tight junction (versus 
monoculture). With this, Chowdhury et al.28 observed increased mRNA of Occludin once 
bronchial epithelial and endothelial cells are cultured together. Even without immune cells, 
the advantages of co-culture can reflect how particle influence inflammation. A co-culture of 
alveolar epithelia with pulmonary endothelial shows increased barrier but also increased IL-6 
and IL-8 during the exposure to the environmental pollutant, cadmium (Cd2+).29 
1.2. Lung Cystic fibrosis  
Cystic Fibrosis (CF) is a genetic autosomal recessive disorder caused by mutations in 
the cystic fibrosis transmembrane conductance regulator (CFTR), an ABC ion channel 
transporter of chloride regulated via cyclic amp (cAMP). This disease is followed by cardinal 
traits affecting organs like pancreas, liver, intestine, and the lungs with significant airway 
obstruction and P. aeruginosa infection.30 
Mutations in the CFTR or Cystic Fibrosis transmembrane conductance regulator can 
impair the transport of chloride and water transport on epithelial cells, especially in the lungs; 
such conditions make CF a genetic, life-threating disease31. F508del is the predominant 
mutation (70% patients) from the 5 mutation classes of CF, and it brings translational 
alteration issues to this receptor protein. By removing a single amino acid on CFTR, it does 
not allow the protein to maintain its 3D shape, which triggers the cell’s mechanisms of error 
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and disposal of this protein32. The mutations are defined as classes in which I) no CFTR 
synthesis, II) process blockage of CFTR, III) regulation blockage of CFTR, IV) differential 
CFTR conductance, and V) reduced CFTR production33. 
Chloride and combined sodium hyper-absorption in the airway surface liquid alters 
mucus viscosity, allowing more adherence to the epithelial layer that consequently stops the 
regular ciliary function34. This results in bacteria not being cleared, adhering to thick mucus, 
and indirectly on the epithelia, settling persistent infections. Those infections will then trigger 
inflammation and immune response to be excessive, leading to tissue damage 35. 
The molecular role of CFTR impairment is still to be confirmed, and mechanisms to 
explain the alterations are being investigated. Smith et al36 observed CF lung epithelia does 
not secrete antibacterial components anymore. Instead, the antibacterial activity was only 
recovered by the supplementation with sodium chloride. This created a high salt hypothesis in 
which the impairment of CFTR in controlling ion affects salt levels, and this would decrease 
the activity of defensins, natural antimicrobial peptides.  
The low volume hypothesis comprises sodium flow and inhibition of the epithelial 
sodium channel (ENaC)37 by CFTR mutations. This consequently alters the flow of chloride 
ions with resulting surface dehydration and thickening of mucus38. The last explanation of the 
role of CFTR involves the cultivation of airways gland cells. Those cells release specific 
secretions containing antimicrobial proteins; however, the production of this secretion only 
occurs when CFTR is well-functioning39.  
1.2.1. Interactions with the immune system: inflammation versus infection 
When a pathogen enters the respiratory tract, there is the airway epithelium with a 
tight cell-to-cell barrier and the presence of mucus/lining fluid with antimicrobials. At the 
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basis of this defense, the epithelium detects the presence of foreign DNA with Toll-like 
receptors, pattern recognition receptors, etc40.  
The first checkpoints of microbes are a subset of immune cells but also dendritic cells 
and alveolar macrophages41. An array of lipid mediators and chemokines start the recruitment 
of effector immune cells. In this communication, CXC chemokines and cytokines (IL-1α and 
IL-1β, IL-10, IL-17, IL-23, IL-25, IL-33, and thymic stromal lymphopoietin) control the 
regulation of inflammation42. 
Dendritic cells (DCs) and macrophages can engulf bacteria via interferon-γ, but those 
cells will also present antigens to start activation of T lymphocytes (CD4+ and CD8+) and 
release cytokines (for instance, IL-6) to mature B lymphocytes, integrating the adaptive 
immune system43. 
The regulation of inflammation is tightly attached to context and time. Similarly, 
enzymes like neutrophil elastase or MMP can destroy bacterial proteins, but its excess can 
degrade the extracellular matrix and harm the lung tissue44. In respiratory diseases, it is 
common that immune cells fail to resolve infection leading to chronic state and excessive 
inflammation, as in the cases of cystic fibrosis and COPD45. 
The main issues the CF patient has to deal with are: 
• Defective CFTR leading in impairment of water and chloride transport,46  
• thickening of mucus with abnormal elasticity47,  
• airways blockage48,  
• slowing towards ineffective mucociliary clearance,  
• inactivation of antimicrobial molecules on mucus/surface lining fluid49 and  
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• opportunistic bacterial and fungal infections that evolute to biofilm formation50.  
 In consequence, these manifestations will alter host immunity, especially the innate 
immune system. This exposure to pathogenic organisms demands a warning system, but a 
system that acknowledges what a threat is and how much response is required before 
inducting tissue destruction. For that, the pathogen-associated molecular patterns (PAMPs) 
are the critical signals for microbes to be recognized as foreign. From that concept, the family 
of Toll-like receptors started to be uncovered as the first stage on using microbe patterns, 
bind to those and initiate the response.51 
 CFTR coordinates the functionality of the nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-қB), and its lack of regulation will lead to an increase in IL-8 in the 
consequent neutrophil invasion, lung injury and allow for bacteria development into biofilms 
(see figure 5). Because of one of the primary mutations in CF, CFTR does not transcend to 
the cell membrane and to its lipid rafts, where it starts the control of inflammation via NF-қB. 
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Figure 5. Impairment of CFTR functionality provokes inflammation triggering excessive inflammation. 




 If inflammation is not controlled during CF mutations of CFTR, the molecular events 
must be uncovered. For immune cells, when facing an antigen, there is either direct uptake or 
extraction of some of the antigen components. The outer core oligosaccharide of the 
lipopolysaccharide (LPS) in the outer membrane of Pseudomonas aeruginosa initiates an 
immune response, and its endocytosis leads to NF-қB translocation. On the lung epithelium, 
CFTR is a non-classical site for attern recognition molecules to extract and internalize LPS. 
This regulation is  wholly altered during the failure to produce a complete and translocated 
CFTR.53 
 If CFTR recognizes P. aeruginosa, it starts the production of other signals as IL-1β, 
so alterations of this receptor, as in CF, can bring dysregulation also of this main cytokine. 
This cytokine influences transcription factor as MyD88 and, once more, NF-қB. 
Polymorphisms on this cytokine’s gene have been associated with loss of control of 
inflammation and lung disease severity in CF patients54.  
 If the release of cytokines is disrupted during CF, the recruitment of immune cells is 
also influenced. CFTR in primary monocytes was shown to increase calcium on levels that 
would alter gene expression, and for that, in the view that neutrophils, macrophages, and T 
cells are recruited, there is a reduction in the activation of those immune cells.55 One of the 
main consequences of this inactivation is also leading to influence on cell homeostasis in 
which the production of glutathione is decreased (the main issue on the control of reactive 
oxygen species)56 and on the increase of prostaglandins57. Finally, incomplete CFTR 






Figure 6. Alterations of the immune system due to mutant CFTR. Reproduced from 55. 
 
1.2.2. Predominant infections in cystic fibrosis 
 The CFTR alterations result in the formation of obstructive airway plugs and impaired 
cilia beating. Those alterations over time create a new lung microenvironment, one that 
fosters the infection by S. aureus, followed by P. aeruginosa. 58 
Age does influence the type of infection, and microbiological identification methods 
like agar plating are not enough to distinguish the infection. For that, studies on the CF lung 
microbiome are progressively seen as more suitable. Fig. 7 shows the 16S microbiome results 
of one patient along a decade of CF, with infection and antibiotic exposure59. This extends 
CF infections to be dominated by P. aeruginosa, but never exclusive of it. It includes 
Haemophilus influenzae (a cause of exacerbations in children), Burkholderia cepacia, 






Figure 7. The bacterial community of a cystic fibrosis patient along one decade. 16S microbiome from 18 to 28 
years of age showing the abundance of operational taxonomic units (OTUs) with a scale of BETR (baseline, 
exacerbation, treatment, recovering) and heat map of the antibiotic load. Reproduced from 59 
 
 As observed, the CF lung is colonized by many microbes and the airways epithelial 
cells are infected continuously by bacteria, viruses, fungi, and virulence factors. Those 
organisms become part of the lung, forming an ecological community of natural microbes, 
the microbiome60. From the beginning with real-time polymerase chain reactions, passing by 
pyrosequencing and mRNA sequencing, the methods to define the microbiome have changed, 
and with those, it is possible to advance the stratification and understanding of healthy and 
diseased patients (along time, along with treatment, along with exposure, etc.)61 
 Already in asthma and COPD, the lung microbiome presents insights into the 
mechanisms along with disease progression, and this can be further investigated with in vivo 
models of, for instance, the influence of other microbes on allergen tolerance.62 For CF, the 
lung microbiome brings the complexity of the polymicrobial infection that has altered the 
way we understand infection, and for that, we can observe this dynamics63. The airways 
might maintain its homeostasis precisely because of its interaction with the microbiome, 
including in properties as barrier formation; counting with the note that all inhaled particle 
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and microbes are fastly uptaken to be killed, but also, in the end, to stimulate and build the 
memory of our immune system. 64 
1.3. Pseudomonas aeruginosa lung infection 
 Pseudomonas aeruginosa is an opportunistic and ubiquitous Gram-negative bacillus 
colonizing multiple environmental niches, but acute infection comes with fragile immune 
response, for instance, in patients from intensive care units. Nonetheless, it is the chronical 
bacterial lung infection that accounts for the majority of the morbidity and mortality seen in 
the disease. This state is governed by the production of polysaccharide as alginate and 
mucoid exopolysaccharide leading to bacterial adherence to host cells and in evasion of the 
host immune response.65 
 The alterations derived from CFTR mutations bring severe issues for the respiratory 
system, but it is the infection with P. aeruginosa that worsens the clinical symptoms. With 
that, respiratory failure occurs in 80% of CF patients because of the chronicity and disease 
evolution.66  
Gene expression and the virulence factors of P. aeruginosa are the needed machinery 
for this bacterium to adapt67, and as seen in figure 8, there are many tools to influence the 














Figure 8. P. aeruginosa has an array of strategies fights against host defenses to promote bacterial adaptation, 
including these virulence factors. Reproduced from 58 
 
 P. aeruginosa infection demands several factors for bacterial adaptation, but to reach 
chronic disease some changes are required as: gene exchange for antibiotic resistance, 
slowing metabolism with consequent decreased growth, restrain of motility with adherence 
on the epithelial layer, hinder of bacterium communication (quorum-sensing) and production 
of its own matrix, based on alginate.68 
 The fluctuations in gene expression are required to promote the transition from 
planktonic to biofilm69. For that, the network or kinases are regulators of this transition when 
the RetS-Gac-RsmA system regulates the interaction with the host (by coordinating the 
release of toxins from the type III secretion system (TTSS) and the production of the 
extracellular polysaccharide matrix, producing P. aeruginosa-specific polymers psl and pel, 
leading to the pellicles, or bacterial aggregates in air-liquid interface.70 Studies on the 
chemical nature of those systems can bring an understanding of how to control this transition. 
 Not always, P. aeruginosa succeeds in establishing an infection in humans because 
the pressure from our immune system can be sufficient; however, this pressure can activate 
the expression profile of hyper-mutator strains. Because of the establishment of infection, 
neutrophils, for instance, release oxidative stress, via ROS or reactive nitrogens. This is a 
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valid strategy to alter bacterial lipids, but for the surviving bacteria, those variants are now 
selected to maintain guard facing the host challenges.71 
 When pressure from the host is on, regulation of virulence and motility is needed. For 
that, mutation on the mucA gene will produce mucoid strains or mutations on psl, and pel will 
creat small-colony variants; moreover, the glycosylation of LPS will hinder recognition by 
immune cells or mutations on lasR and homoserine lactone system will stop production of 
elastase, pyocyanin and etc72–75. 
 Our immediate reaction to infections is antibiotic treatment, and this does create 
another pressure for bacterial killing. However, the resistance to antibiotic therapy is a known 
trait for P. aeruginosa68. In reports, systems as MuxABC-OpmB are essential genes on 
avoiding the efficacy of novobiocin, aztreonam, macrolides, and tetracycline, as well as 
MexXY efflux system on aminoglycoside efficacy76,77. Surprisingly, acquired antibiotic 
resistance is linked to mutations of regulatory genes from virulence functions in P. 
aeruginosa76, which shows that heterogeneity is a must.  
1.4. Current treatment for lung CF infections 
People living with Cystic Fibrosis (CF) account for 70,000 worldwide32 that require 
hospitalization and efforts on drug development toward pulmonary and nutritional therapies. 
In the pipeline of drug development, researchers have contributed to the restoration of CFTR 
function, mucociliary clearance, anti-inflammatories, anti-infective (including inhaled 
Tobramycin powder), and nutritional supplements. However, this same pipeline shows only 4 
approved anti-infectives out of the 11 drugs on development78. Besides the approval of new 
drugs, the discovery of new antibiotics has suffered a decrease along decades and this is not 
only the case for Cystic Fibrosis.  
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Antimicrobial discovery had golden times in the 1960s with natural products from 
Actinomycetes in which we obtained tetracyclines, aminoglycosides, and other non-beta-
lactams drugs79. Nonetheless, microbes have their resources to prevent drug penetration, and 
mainly, the development of resistance and resistance-acquiring mechanisms have dampened 
drug discovery. Still, the search for natural compounds has changed with the collaboration 
with genomic sciences: an evolution towards the detection of metabolites. Besides 
metabolomics,  new screening methods have led to new compounds80, showing only 
increased complexity brought further advantages. 
With the advent of ESKAPE organisms (Enterococcus, Staphylococcus aureus, 
Klebsiella species, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter)81, the 
resistance problem gets worsen by persister cells and biofilm formation allied with absent 
metabolism that is the main target of antibiotics. New research towards adjuvant drugs been 
developed on account of the understanding of virulence pathways with pathoblockers and 
quorum-sensing inhibitors being revealed82.  
On the treatment of CF lung disease, progress was made on innovation and drug 
delivery. On fig. 9A, the recommended antibiotics in CF therapy are currently 
commercialized in formulations focusing on pulmonary drug delivery. Through lung 
application, the drug can reach the site of infection, and thereby being more active against the 
bacteria while avoiding the development of bacterial resistance. On figure 9B, we observe 
that besides antibiotics, other options of treatment have been explored, either targeting 
bacterial biofilm, the excessive inflammation in the lungs, or the correction of CFTR defects. 
Nanotechnology offers the possibility to improve CF lung treatment, through the on drug 
protection/retention, the access to the core of biofilms, the uptake by the host cell and control 
of particle deposition. All those advantages are described in Figure 9C and aim to prevent 



















Figure 9. CF therapy: from inhaled antibiotics to CF correctors. A) Current commercially available inhaled 
antibiotic formulations. B) Summary of novel agents in the pipeline for CF treatment. C) Engineering of 







1.5. Models for P. aeruginosa infection in cystic fibrosis  
Testing platforms of new, old, and improved drugs have changed from bacteria alone 
to bacteria growing on the presence of cells. It was clear that microbes were not alone and 
were influenced by other bacteria in the environment84 or bacteria-derived molecules and the 
presence of the host85. Interestingly, microbes as P. aeruginosa have been outed as saboteurs 
of new drugs or beneficial molecules (e.g., Cif factor blocking a CFTR corrector86 and 
bacterial hydrolases stopping resolving lipid mediators87), but, most importantly, those 
discoveries were only possible by integrating bacteria and human cells to then proceed with 
treatment. 
1.5.1 In vivo 
 One of the most accessible models of CF is the mouse; however, the introduction of 
CF-related mutations has not provided spontaneous disease. Nonetheless, this model can be 
altered with the stimulation by bacteria, creating an infection/inflammation scenario.88 
 CFTR deletion is one approach. However, other receptors mimic CF disease 
progression. On mice, the overexpression of the epithelial sodium channel (β-ENaC) 
influences in the volume of airway surface fluid, on producing blockage by mucus with lung 
injury and chronic inflammation.61 
The mice model requires special attention as it shows a failure to thrive, mortality and 
excessive responsive to infection that is not reflected by human CF89. For that, other models 
are presented, in an attempt to overcome some of those issues, but also to provide disease 
progression in the lung. 
Besides mice, large animals have also been used in CF research. Lung pathology, 
excessive responsive of the airways and alterations on surfactant started to be investigated on 
the pig CF model, due to its comparative anatomy90. CFTR deficiency presented changes in 
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tracheal development and gastrointestinal blockage, but only the aging pig gave similar lung 
problems in its function that are found in CF infants (although there is the question if those 
were exclusive of the introduced defects on CFTR)91. It is an exciting model that demands 
high costs for husbandry with extended reproduction cycle92. 
Although other animals have been described for CF models, as monkey93 and sheep94, 
the ferret is the third most used animal. The knockout of CFTR in the ferret brought neonates 
with defects on chloride transport and alterations on submucosal glands. Yet an improvement 
on animal models, biological tools against ferrets antigens are scarce.95 
1.5.2 In vitro 
Using in vitro models and cell lines is a relatively new concept to mimic different 
aspects of CF and to develop new platforms for drug discovery and drug testing11.  
Notably, the lung from the trachea to the alveolar region encloses more than 10 cell 
types and especially the bronchial area, or upper airways count with ciliary structures, mucus, 
and surfactant fluids 96. Considering such in vivo complexity, the establishment of an in vitro 
cell system that could minimally mimick the diseased airway is instead a not simple task. 
Therefore several groups, including us have established several co-cultures models, 
constituted minimally by two cell types (usually epithelial and immune cells)97,98. This 
combination goes beyond the traditional classical cultivation of cells as monocultures, while 
allowing to access parameters like increase inflammation, excessive immune cells recruiting, 
tissue damage due to matrix-breaking molecules and failure of bacteria control99.  
The bronchial region can benefit from the rolling of alveolar macrophages through the 
air interface nearby the terminal bronchioles100; however, the majority of the bronchial 
epithelium relies on the transmigration of immune cells (macrophages and neutrophils) from 
the basal sub-epithelial space across the epithelium to the airways following infection101–103. 
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Transmigration models have been developed104,105, though still lacking focus on Cystic 
Fibrosis specific issues, including the use of proper diseased bronchial epithelial cells.  
The pulmonary system is comprised of the upper airways, trachea, and primary 
bronchi for lower airways and alveolar for the distal/small airways. This division is useful 
because it demonstrates cell composition being completely different among these regions. As 
well as, cell susceptibility to infection and content of antimicrobial molecules. Besides, for 
CF disease, the lower lung is the area prone to infection with consequent lung re-structure 
and excessive inflammation.106 
 Human primary bronchial epithelia can be obtained through biopsies, explants, and 
some factors as cell´s yield, bacteria colonization from the host, and lung injuries turn the 
procurement of primary cells a fair challenge. Other options as airway brushings or use of 
content from bronchoalveolar lavage and nasal swabs are being used, although cell counts are 
lower even more scarce in CF patients.107 New technologies gave us access to the 
development of patient-specific cells as basal stem cells, transdifferentiation from type-II 
alveolar into type-I cells, inducible pluripotent and embryonic stem cells.108,109 
 From primary cells to immortalization, bronchial cell alveolar models, have brought 
the needed requirements for long-term cell culture with the advantages of cell differentiation 
and possibilities to develop scenarios of disease progression, including acute to chronic 
infection.106 By growing cells on plastic dishes/wells or the permeable porous membrane, it is 
possible to mimic such scenarios. The figure 10A shows that cell models of the bronchial 
area can now be cultivated at air-liquid interface, in double to triple cell-culture, besides also 
the possibility to include extracellular matrices and shear stress (either of air and liquid). That 
has provides insights into the characterization of CF immortalized cells, as CFBE41o- cell, 
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which express mature receptors as TLR1-5 and 9 as well as healthy bronchial cells 
16HBE14o110. 
 Advancing on the models (fig. 10B), the inclusion of immune cells has now provided 
differences in between non-CF versus CF cells (NuLi versus CuLi-1 with F508 CF mutation) 
on increases inflammation in the presence of CFTR defects, including increased neutrophil 
migration111. This co-culture with immune cells has been used not only for the analysis of 
drug delivery methods but also on CF infection as the inclusion of S. aureus.104,112,113 
Besides the influence of the host, the outcome in CF disease will also be influenced by 
the bacteria growth, more specifically by the transition from planktonic to biofilm form.  
Marquis-Moreau et al114 has demonstrated the use of co-cultures to observe early biofilm 
formation on top of CFB41o cells after 6 hours of P. aeruginosa infection (fig. 10C) and this 
model has now led to increased understanding of biofilm control, drug efficacy, and 
antibiotic resistance115. 
If early P. aeruginosa colonization of lung can now be mimicked in vitro, the 
establishment of a mature biofilm on epithelial cells is still a challenge. The infection itself is 
highly toxic to epithelial cells – no longer than 6 hours, the epithelia is not viable anymore, 
remaining, therefore, only the bacteria. This limit further studies on bacteria-host cell 
responses in the long term infection. Thus, different strategies are being used since the 
external growth of biofilm and transfer of its content116 as well and biofilm growth into gels 
in the separated compartment but still the same well with airway epithelial cells (fig. 10D)117. 
The increase of in vitro cell complexity has demanded the development of new 
models that explore lung regions, cell types, cell differentiation, cell source, diseases versus 




Figure 10. Summary of in vitro of CF and its inclusion of bacteria. A) Airway epithelial cells (AEC) and its 
variation, from monoculture to polarization with ALI, the addition of fibroblasts, co-culture with antigen-
presenting cells, the inclusion of collagen matrix and shear stress. B) Co-culture for neutrophil transmigration. 
C) Growth of P. aeruginosa early biofilm (6 hpi) on CFBE41o- cells in a flow cell. D) Inclusion of mature 
biofilm aggregates. E) Dual microbial infection of P. aeruginosa and S. aureus on top of CFBE41o- cells. 








2. Aim of this work 
In this study, we have developed a new air-liquid interface 3D in vitro cell co-culture 
constituted by CF bronchial epithelial cells (CFBE41o-) and differentiated macrophages 
(THP-1),  infected with P. aeruginosa.  
This model approaches the manner we think on drug discovery towards new 
antibiotics because it challenges that an analogical view on kill versus not killing bacteria. 
This drug testing should be recommended to test bacteria that are grown on live substrates. 
First, to understand how bacterial adaptation could protect them from antibiotic action and 
second, to comprehend the dynamics of lung cells in the battle of drugs and bacteria. 
If a bacteria can grow on a live surface as the lung epithelia, a second important 
feature is the role of immunity. With the potential to include inflammation as a third 
component, we want to evolve the co-culture for inflammation-producing cells like the 
macrophages. This integration will increase complexity, but it will challenge our capacity to 
understand why antibiotics might not work and how to start thinking of new strategies. 
By uncovering the issues of adherence of these two chosen lung cells in different 
compartments of a transwell membrane, we bring forward the role of macrophage migration, 
inflammatory stimulation/response, while a diseased epithelium presents the formation of 
early biofilm aggregates from P. aeruginosa. Monocultures in comparison to the double co-
cultures were characterized in terms of its features, e.g., morphology/viability of the cells, 
integrity of the epithelial layer, use of cells as substrate for bacterial growth and biofilm 
formation, cell collaboration on induction of inflammation, tobramycin response on bacteria 
survival and host response in a more complex system mimicking the in vivo situation. The 
interplay between epithelial cells and macrophages and bacteria uptake was investigated with 
Confocal Laser Scanning Microscopy (CLSM). 
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3.1. Materials and Methods 
3.1.1 Cells 
3.1.1.1. CFBE41o- Cystic Fibrosis Bronchial Epithelial cell culture 
 CFBE41o-, derived from a cystic fibrosis patient and homozygous for ΔF508 
mutation,120,121 was received as a kind gift from Dr. Dieter C. Gruenert (University of 
California, San Francisco, CA, USA). The cells (passage number 4.60 - 4.80) were 
maintained in MEM (Gibco™ Thermo Fisher Scientific Inc., Waltham, MA, USA) 
supplemented with 10% FCS (Lonza, Basel, Switzerland), 1% non-essential amino acids 
(NEAA, Gibco™) and 600 mg/L glucose (Sigma-Aldrich) at 5% CO2 atmosphere and 37°C, 
respectively. Cells were fed every 2-3 days. For co-culture experiments, cells were seeded 
with a density of 200,000/well in 12 well Transwell® plates (500 µL MEM apical side, 
1.5mL MEM basolateral side) with a PET membrane of pore size of 3 μM (Corning, 
Amsterdam, Netherlands). Cells were lifted to the air-liquid interface (ALI), 3 days after 
seeding, and fed every 2 days until cells formed a confluent monolayer and barrier properties 
exceeded 300 Ω*cm² (typically 7 days after seeding). 
3.1.1.2. Macrophage culture and differentiation 
 The THP-1 cells (No. ACC-16), a monocyte-derived cell line122, was obtained from 
the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ; Braunschweig, 
Germany). The cells were grown in T75 culture flasks using Roswell Park Memorial Institute 
(RPMI) 1640 medium (Gibco® by Lifetechnologies™, Paisley, UK) supplemented with 10% 
FBS. Before using them in experiments, the suspension cells were differentiated by adding 10 
ng/mL PMA (Sigma, Germany) to cell culture medium123 and further incubated for 48 h 124. 
Accutase® (0.5 mM EDTA•4Na, Sigma, Germany) was used to remove cells from flasks. 
 For cell number optimization, we used ImageJ to count cells using different cell 
density and incubation together with CFBE41o- grown on transwells. After obtaining 
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imaging with confocal microscopy, we used the transferred image and opened it with Fiji. By 
converting to RGB, we can then adjust threshold and observe the structures we will count. By 
subtracting the background and using the watershed program, we can adequately define the 
edges of the particles. We then use “Analyze particles,” setting size 0-Infinity and circularity 
0-1, then each particle is numbered and counted. 
3.1.1.3. QuasiVivo® flow system 
 A bioreactor (Quasi-Vivo, QV600, Kirkstall, United Kingdom) that is also a perfusion 
chamber with a peristaltic pump is commercially used and was used for the testing of 
CFBE41o- differential growth. The cells were cultivated on 0.33 cm2/0.4 µm pore size 
transwells for 1 day on adherence in liquid-covered conditions. On the next day, transwell 
upper rings were manually cut to fit the flow chamber, then transferred to the flow chamber 
or remained as static. Importantly, transwells were installed, so only the basolateral side has 
contact with the medium and the flow, therefore maintain the air-liquid interface. Using 
CFBE41o- cell medium on reservoir bottles, we tested 0.5 and 1 ml/min as flow rates 
compared to static conditions along 6 days using a cell incubator (37oC, 5% CO2), with 
measurements of TEER everyday and cytotoxicity assays (MTS, Promega, Germany and 
LDH, Roche, Switzerland), according to the manufacturer’s recommendations. 
3.1.2. P. aeruginosa (PAO1-GFP and PA14) cultures 
 P. aeruginosa strain PAO1, its fluorescent-labeled strain ATCC® 10145GFP™, and 
PA14 were grown in LB broth (Sigma-Aldrich, Germany). For the GFP expressing strain, the 
LB medium was supplemented with 300 μg/ml ampicillin (Carl Roth, Germany). Overnight 
cultures were grown by inoculating 15-20 ml of LB broth with a single colony of bacteria and 
incubating for 16-18 hours at 37°C and 180 rpm. For cell infection, an overnight culture of 
PAO1 in exponential growth phase was PBS-washed and diluted to a final OD600 0.1 (~ 
1x107 CFU/mL) in MEM cell medium. 
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3.1.3. Set-up of the 3D co-culture model 
3.1.3.1. Uninfected 3D co-culture 
 Setting-up the co-culture was performed based on Ding et al104 with modifications. To 
visualize the mono and co-cultures, CFBE41o- cells were labeled one day before the set-up 
of co-culture with CellTracer Far Red (1µM, Sigma, Germany) and when needed THP-1 cells 
with 10 µM CellTracker. The medium from CFBE41o- monolayers was removed (from both 
apical and basolateral chamber), and the inserts with the established epithelial layer were 
turned upside down. The cells that overgrown through the membrane pores in the basal side 
were removed with a cell scraper. Then the transwells were deposited in sterile glass Petri 
dishes (50 x 200 mm, Normax, Portugal). 
Differentiated THP-1 macrophages were harvested, suspended in RPMI 1640, and 
200 µl of the cell suspension (2x105 cells/well, which corresponds to 1 macrophage:1 
epithelium ratio125) was added to the basal side of the inserts turned upside down. The Petri 
dishes were closed and incubated for 2 h at 37°C/5% CO2. Afterward, the Transwell inserts 
were placed back into the plates and 0.5 ml CFBE41o- cell medium was added to the lower 
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 3.1.3.2. Infected 3D co-culture 
Double cell co-cultures were either infected with P. aeruginosa PAO1-GFP (ATCC® 
10145GFP™) or incubated with LPS E. coli 10µg/mL for testing potential inflammatory 
response. 
Overnight culture of PAO1-GFP in exponential growth phase was PBS-washed and 
diluted to an OD600 for a final concentration of 2x105 PAO1 cells (Multiplicity of infection 
MOI 1:1) of bacterial suspension in 100 μl of MEM medium for 1h on the apical side to 
infect wells; afterward the apical medium was removed and the bacteria on top of epithelial 
cells were exposed to the air. 
A stock of tobramycin sulfate salt (1mg/mL in PBS, Sigma, Germany) was diluted on 
Phosphate Buffer Solution (PBS, pH 7.4). A volume of 500 μl of the drug solution was 











3.1.4. Transepithelial Electrical Resistance Measurements (TEER) 
 To assess the epithelial barrier properties, CFBE41o- mono and co-cultures were 
incubated with cell medium (500 μl apical and 1500 μl basolateral) for 1 hour, and TEER was 
measured with an epithelial volt-ohm meter (EVOM, World Precision Instruments, Sarasota, 
FL, USA) equipped with STX2 chopstick electrodes. The TEER was calculated by 
subtracting the resistance value of blank inserts containing only medium (120 Ω for 1.12 cm²) 
from all samples, with further multiplication by the cultivation area of the inserts. 
3.1.5. Confocal Laser Scanning Microscopy 
3D and cross-section images were obtained by CLSM (Leica TCS SP 8; Leica, 
Mannheim, Germany), using lasers at 405 nm (DAPI), 488 nm (GFP), 505 nm (Yellow) and 
633 nm (Far Red). Microscopic images were acquired at 1024 × 1024 resolution, using a 25x 
or 63x water-immersion objective. Zeta-stack mode (10-15 stacks) was used to build a three-
dimensional model of the co-culture, in which cross and orthogonal sections were used to 
observe macrophage transmigration and bacteria phagocytosis. Confocal images were 
analyzed using Analysis was performed using LAS X software (Leica Application Suite X; 
Leica, Mannheim, Germany).  
3.1.6. Fixation and Immunostaining of zona occludens (ZO-1) 
Immunohistochemical staining for the TJ protein ZO-1 was performed as previously 
described109,126 with minor modifications. Briefly, system the cells were fixed with 3% 
methanol PFA (stock 16%; 15710-S, Electron Microscopy Sciences, USA) in PBS from 
apical and basolateral side for 1 hour. The following steps, including quenching, blocking, 
permeabilizing, and staining were then performed from the apical compartment of cocultures 
and monocultures. In brief, the samples were quenched with 150 µL of 50 mM NH4Cl in PBS 
for 1h, followed by a blocking and permeabilizing step using a mixture of 0.5% BSA / 
0.025% Saponin in PBS for 1h min at room temperature (RT). The primary antibody against 
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ZO-1 (Purified Mouse Anti-Human ZO-1 Clone  1/ZO-1  (RUO), Catalog No. 610966, BD 
Biosciences) was diluted 1:200 in 0.5% BSA / 0.025% Saponin/PBS-solution; 200 µL was 
then added apically, followed by incubation at 4°C overnight. The secondary antibody 
(polyclonal Alexa-Fluor 633 conjugated rabbit anti-mouse, Catalog No. A11059, Invitrogen) 
was diluted 1:2000 in 0.025% Saponin/PBS-solution and incubated for 2h at RT. The 
samples were washed with PBS and counterstained with DAPI (1:10000, 0.5 µg/mL; 30 
minutes) and/or rhodamine-phalloidin for staining of F-actin (Invitrogen, Germany; 20 μM in 
methanol for 2 hours). Transwell® membranes were then cut out of the filter insert structure, 
mounted in between two glass coverslips and a drop of DAKO mounting medium (Product 
No. 85 S302380-2, DAKO, USA), then analyzed by CLSM. 
3.1.7. Cytotoxicity assay: the release of lactate dehydrogenase (LDH) 
LDH was calculated about negative (medium only, 0% cytotoxicity), and positive 
controls (1% Triton-X100, ICN, Eschwege, Germany, positive control, 100% of 
cytotoxicity). The supernatant of cells infected or not infected was placed in a new 96-well 
plate and centrifuged (5000 RPM for 10 minutes), then 100 µL of supernatant was separated 
for LDH assay (Roche Cytotoxicity LDH kit, Germany). LDH kit mix was incubated with the 
supernatants for 5 minutes in the dark at room temperature, according to manufacturer 
instructions. The absorbance was read by a Tecan microplate reader (Germany) at 492 nm. 
3.1.8. Colony-forming units (CFU) assay  
After the specific time points of infection, supernatants were removed, sterile MilliQ 
water was added on the wells for cell lysis (15 minutes) then samples were stored at -20°C. 
The supernatant was centrifuged to separate the pellet of bacteria, then stored at -20°C. For 
plating, samples were re-suspended in PBS, serially diluted in PBS/Tween80 0.05%, and 
drop-plated (3x 20µL drops per dilution) on agar plates to determine the CFU. 
Adherent/internalized bacteria on transwells were scraped using a pipette, then serially 
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diluted and drop-plated. LB-Agar plates were incubated at 30°C overnight for 24-76 hours, 
colonies were counted, and CFU calculated accordingly. 
3.1.9. Enzyme-linked immunosorbent assay (ELISA) of cytokines 
Pro-inflammatory cytokines were detected on the supernatant of infected cultures with 
the Cytokines ELISA Ready-SET-Go kits (Affymetrix eBioscience, USA). Briefly, Nunc 
Maxisorp® 96-well plates were coated with capture antibody of the respective cytokine and 
incubated overnight at 4°C. A series of washes were performed with Wash Buffer 
(PBS/Tween20 0.05%) then wells were blocked by incubation with ELISA/ELISPOT Diluent 
for 1 hour. Samples were applied (or previously diluted, in the case of IL-8 plates) together 
with kit cytokine standards, and plates were incubated overnight at 4°C. Plates were washed 
then received detection antibody of the respective cytokine for 1 hour RT incubation. Another 
series of washes were performed and plates received Avidin-HRP for detection of 
biotinylated antibodies for 30 minutes. The last series of washes were performed and the 
TMB solution was applied as enzymatic/color inductor from the kit. The reaction was 
stopped with 1M H3PO4 solution and absorbance (Spectrophotometer; MultiskanGo 1510, 
Germany) was read at 450nm for detection and 570nm as background. Values were paired 
with an internal calibration curve from the cytokine standards well and then properly 
calculated to the sample wells. 
3.1.10. Multiplex cytokine panel with Flow Cytometry 
In order to quantify the cytokines Panel I (IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, 
IL-17A, IL-17F, IL-21, IL-22, IFN-γ and TNF-α) and Panel II (TSLP, IL-1α, IL-1β, GM-
CSF, IFN-α2, IL-23, IL-12p40, IL-12p70, IL-15, IL-18, IL-11, IL-27, and IL-33) secreted by 
uninfected, infected not treated and infected tobramycin-treated, we used LEGENDplex™ 
Immunoassay according to the manufacturer's instructions (Biolegend, USA). 
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3.1.11. Measurement of P. aeruginosa virulence factors: pyocyanin and pyoverdine 
CFBE41o- mono and co-culture (200,000 cells/well) were cultivated on 24-well 
microplates until 80% confluence (3 days of growth). P. aeruginosa PA14 strain was 
cultivated for 18h in 200ml-Erlenmeyer, incubated at 37oC, 200rpm, 75% humidity. On the 
next day, the content was transferred to a 50mL-Falcon and centrifuged at 5000 RPM for 10 
minutes. The content was then PBS-washed and its optical density (λ=600nm) was measured 
at the spectrophotometer. Bacteria suspension was adjusted to a final OD of 0.02. 
PPGAS medium or medium with candidate compounds was filled in each well of 
1.5mL, then for each well 15 µL of the bacterial suspension was given to have a multiplicity 
of infection of 1:40 (cell to bacteria). The cells were infected, infected treated or non-infected 
for 18 hours in which the plates were covered with a BreathSeal cover (Greiner, Germany). 
After incubation, the seal was removed, and the content of each well was transferred to a 
plastic tube. The following methods were validated and described by Thomann et al82. 
Before the extraction of pyocyanin, 100 µL of each sample transferred to a black 
transparent 96-well plates (Greiner BioOne, Germany) and pyoverdine was measured through 
Fluorimeter (Excitation 400/Emission 460nm; TECAN Infinite M200Pro, Austria). 
For pyocyanin, the method has been previously described by Kurachi (1958). 
Thomann et al.82 used 900 µL 100% chloroform per plastic tube, then proceed to 
centrifugation at 14K RPM for 15 minutes. Each tube formed 3 phases, we transferred the 
organic phase into a new plastic tube, followed by the addition of 250 µL of 0.2M HCl and 
centrifugation of 14K RPM for 10 minutes. Pyocyanin was measured from the aqueous phase 
at the spectrophotometer (520nm). 
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3.1.12. Statistical analysis 
Data represent 3 independent experiments and are shown as mean ± standard 
deviation (SD). One or Two-Way ANOVA with Tukey´s posthoc test was performed using 
GraphPad Prism 5 software (GraphPad). 
3.2. Results 
3.2.1. Optimization 
Three-dimensional models require advanced cell culture methods to comprise 
different cell types, induce cell polarization, create compartments that mimic biological 
barriers or access to the systemic blood network. These and other requirements demand the 
use of a platform that provides a connection between the created compartments. Most of the 
available 3D in vitro models were established on permeable filters (Transwell® system). 
Different surface area, material, thickness, different pore size, and density are some of 
the few variables when choosing a transwell. Although this system has been extensively used, 
an adaptation of new cell lines requires attention on growth rate, cell attachment, 
differentiation and growth area. Optimization of cell number, method of cultivation, cell 
medium, and time of incubation is presented here for CFBE41o- in comparison to another 
bronchial epithelial cell, Calu-3. 
When the cell adheres and differentiates on the apical side of the transwell, the 
communication between cells increases and gives space for the formation of tight junctions. 
This is constantly monitored and characterized here via measurement of the transepithelial 
electrical resistance. After defining differentiation, it was necessary to understand and test the 
adaptation of P. aeruginosa on top of the newly formed epithelial layer. However, our 
challenge was the integration of macrophage-like cells, derived from the activation of THP-1 
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monocytic cells, in the basolateral side of the transwell that contains the grown epithelial 
layer. 
A subsequent optimization was required on macrophage number and time of 
incubation for adherence, plus an observation of how epithelial cells behave and grow in 
contact with medium from another cell. Once the co-culture is established, cell overgrowth 
was observed and demanded changes in the protocol. As we are in demand for a model that 
mimics excessive inflammation, LPS was firstly used as a stimulant antigen, while key 
cytokines were measured to start the characterization of the co-culture. Finally, the infection 
of the co-culture using P. aeruginosa required further elaboration to then provide us the in 
vitro model that can predict host-response and drug efficacy. 
3.2.1.1. Growing CFBE41o- cells on transwell pore 3µm 
 Between all factors that can influence the growth of a cell, the substrate is one crucial 
physical aspect that can affect cell growth and differentiation. For conventional assay as 
viability or scratch assay, cells can be easily cultivated on plastic bottoms or coverslips 
(covered with agents to alter adherence, e.g., poly-L-lysine). For more complex systems, one 
can consider the permeable systems, so-called Transwells®. In our model, we used the 
transwell systems for the following reasons: i) possibility to expose the cells in the apical side 
to the air, which is close to the lung physiology, and ii) the porous membrane mimics a 
barrier that dependent on the comprised cells. 
 Cell growth on transwell demands direct visualization with light microscopy to 
control cell confluence and early qualitative cell differentiation. For that, CFBE41o- cells 
were grown on a polystyrene membrane transwell with pore size 0.4 µm (figure 13A). Due to 
cell density number (200,000 cells per well) on the second day, an epithelial layer started to 
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be formed, until the fourth day it shows increased cell density, cell packing and lining fluid is 
observed. This configuration is useful for modeling CFBE41o- as a monoculture. 
 Figure 13A shows the growth of bronchial epithelial cells, Calu-3, followed for 8 days 
in a transwell system that has a pore size of 3 µm. This pore size is a critical factor for our co-
culture model that also intends to follow the transepithelial migration of immune cells. Using 
CFBE41o-, these cells were grown on two transwells of the same material, similar surface 
area, but different pore density distribution along its surface. However, the transwell with 
lower pore density did not provide visualization under the microscope, which leads to an 
issue when monitoring cell growth. 
A comparison between transwell 3462 and 353181 is observed in figure 13B that 
shows that the same cell type and density, being observed in better quality for the lower pore 
density transwell. Through the use of transwell 353181, the cells can easily be visualized and 
monitored. Moreover, this transwell allows the observation of characteristic signs of layer 




Figure 13. Growth of bronchial epithelial cells to optimize the transwell 
system. A) CFBE41o- and Calu-3 growth on 0.4 µm transwell. B) Growth 
comparison of CFBE41o- cells on transwell of different pore density. 
Representative images of 2 independent observations. 
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 On the assessment of functional cell epithelial barrier, the use of measurement of 
transepithelial electrical resistance (TEER) reflects how pore density and size influences on 
the formation of the epithelial layer. CFBE41o- being a bronchial cell line from a diseased 
condition, can be compared to the standard bronchial cell line, Calu-3. With this comparison, 
we observe the establishment of TEER and the barrier of these two bronchial cells to find a 
specific day then for CFBE41o- to be used as model. For that, in figure 14 we observed stable 
high TEER for CFBE41o- in the transwell with 3 µm pore size, which shows the disposition 








Figure 14. TEER comparison of Calu-3 and CFBE41o- on different transwells. N= 2 experiments. 
 A flow system can improve and speed the cell differentiation, and with primary lung 
cells has improved barrier function and increase the production of cilia and mucus when 
compared to static culture127. For us, a CF cell line has ideal growth after 10 days on 
transwell, and we would like to observe faster confluence and barrier formation with the use 
of a flow system. 
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 The available model is a bioreactor, together with a peristaltic pump. The system has a 
silicone chamber with connector tubes attached to reservoir bottles for continuous feeding. 
We used two flow rates (0.5 and 1 mL/min) and adapted the transwells to fit inside the flow 
chambers and at a height to continue to mimic the air-liquid interface. We could then monitor 
TEER development and at day 6 of cultivation to compare cytotoxicity. 
 Figure 15A shows the setting-up for the system, the position where the transwell sat 
inside the flow chamber and micrographs of day 6 of culture to compare flow versus static. In 
this, we observe 1ml/min may interfere with the formation of CFBE41o- lining fluid, but flow 
rate 0.5 mL/min provides apparently increased cell differentiation. Even so there were no 
alterations on cytotoxicity levels on the addition of flow (fig. 15C); stable TEER was reached 
similarly (fig. 15B). In conclusion, this approach is more useful for specific questions around 




















Figure 15. Testing of CFBE41o- growth, differentiation and layer formation on a flow 
system. A) QuasiVivo® flow system inside the flow bench with light micrographs of 
CFBE41o- cells (static and flow). B) TEER results from flow testing. C) Viability (MTS 




3.2.1.2. CFBE41o- cells overgrow through the 3 µm membrane pores over the basolateral 
side 
 One limitation to set-up a co-culture model in a 3 µm membrane pores transwell is that 
the cells seeded in the apical side can migrate through the pores of the filter to the basolateral 
side. As observed in figure 16, a CFDA pre-stained CFBE41o- grown through the transwell 
pores already after day 4 of seeding.  To seed the macrophages on the basolateral side of this 
membrane, the overgrown epithelia were removed from the basolateral side using a cell 














Figure 16. Overgrowth of CFBE41o- cells on 3 µm transwell stained with DAPI (nuclei) and CFDA (cytoplasm). Day 4 (A), 6 (b), 9 (C) and 11 (D). Kinetics of apical and 




3.2.1.3. Optimization THP1-macrophages on the variation of cell density, time of adherence 
and interaction with CFBE41o- epithelia 
 The inclusion of THP-1 cells on the double cell co-culture requires the seeding on an 
inverted transwell that already contains a CFBE41o- layer. We looked into cell density and 
model incubation to observe the maintenance of cell number after adherence and which 
combination keep more macrophages in a shorter time of incubation. This is because, for us, 
the model establishment is only one of the steps for the full infected model, so cells should be 
interacting and ready to be infected. 
We further optimize the seeding of THP-1 macrophages on transwell, by following 
the cell viability of THP-1 with CFDA Cell Tracer®. At least three images per sample were 
obtained, then a counting protocol was applied using ImageJ (as described in Methods).  
Figure 17 shows the data compilation from macrophages seeded on the bottom of a 
3µm transwells in the presence of the CFBE41o- epithelial layer. Using these co-cultures, we 
vary density number of macrophages, the incubation time for the adherence on the transwell 
(1 or 2 hours) and the cell-to-cell incubation time in which the transwell with the 2 cells is 
placed back into microplate for rest and interaction (1, 6 and 18 hours).  
Our focus was to have the shortest time of adherence to be able to go for the next step: 
the infection. So observing adherence and cell-to-cell incubation time, a combination that 
guarantees a high number but with a time that will safely promote adherence was to use 
200,000 cells in 2 hours of adherence and 1 hour of cell-to-cell incubation.  
With fig. 18 shows a sample of the collected images as an example of how the image 
analysis took place. The imaging of 3 fields per sample (in which one area is represented on 
this figure) versus the variations of macrophage integration is presented, and the use of DAPI 





nuclei can be defined and counted as one cell, then this number was compared to the initial 
seeding number.  
 The initial number of macrophages was chosen based on Ding et al 104. From the 
graph, when using 2 hours of adherence and then 6 or 18hours of incubation, there is a lower 
number of macrophages, considering the epithelia can shed vesicles that can activate the role 
of macrophages, but yet to be proven here. In the seeding of 200,000 macrophage cells, 
shorter adherence time (2 hours) and 1 hour of incubation right after that provides the 
presence of approximately 120,000 cells. This is an initial step to use the model with a 
significant number of macrophages that are not aged cells in the model and that are still fresh 






Figure 17. Variation of THP1: cell density, time of adherence and interaction with CFBE41o- cells. 





Figure 18. Variation of 
THP1: cell density, time of 
adherence and interaction 
with CFBE41o- cells. 
Basolateral views of THP1 
adherence: 3 images per 





3.2.1.4. Establishment of non-infected co-culture of bronchial epithelial and THP1 cells 
 The addition of macrophages could finally take place after i) adjustment on cell 
adaptation on the transwell and ii) variation of conditions for optimal adherence of 
macrophages. When putting two cells together, one needs to observe which medium suits 
better for cultivation if its interaction account for cell stress/toxicity and if the barrier from 
the epithelial layer is affected by the other cell inclusion. 
 Figure 19 comprises results on Calu-3 that it was used as a starting point and to 
provide a future model of the non-CF bronchial co-culture model. No significant differences 
were founded on cell proliferation with the different media (Fig. 19A) nor on barrier integrity 
(Fig. 19C). Plus, no significant cytotoxic effect (Fig. 19B) was observed upon the co-culture 
establishment: even if the borderline level of 20% LDH release from Calu3+THP1. At last, 
using confocal microscopy and focusing on the basolateral side, we could find the THP1-
macrophages (Fig. 19D). The use of cross-sections helped verify macrophage presence and 
start of cell-to-cell interactions (Fig.19E). 
 These interactions, even without any external stimuli, could reveal a protrusion of 
macrophages on the basolateral side, but no transmigration. On fig. 20A, macrophages are 
limited to the transwell membrane or below, but specific formations of cell pseudopods and 
possible cell-derived vesicles could be observed. Fig. 20B shows that macrophage behavior is 





































Figure 19. Testing the 
establishment of co-culture in 
Calu-3 + THP1 cells. A) Calu-3 
growth kinetics with epithelia and 
macrophage cell media. B) LDH 
cytotoxicity release of integrating 
THP1 cells to Calu-3 Day 10 on 
transwell. C) TEER 
measurements comparing mono 
versus co-culture after 24 hours of 
establishment. D) Confocal 
micrograph of basolateral side of 
co-culture on transwell 
confirming THP1 and Calu-3 
presence. E) Cross-sections of 
transwell membrane from co-
culture showing macrophage state 
and migration after 24 hours of 
interaction with Calu-3 epithelia. 




Figure 20. THP1-macrophage behavior and morphology. In co-culture (A) with Calu-3 epithelia after 24h, macrophage on co-culture takes globular and horizontal shape with 
or without cell protrusions towards the Calu-3 layer. In monoculture (B), macrophage morphology is wholly flattened, showing the interaction with Calu-3 alters 




 Aiming for cystic fibrosis in vitro model we used the established CFBE41o- cell line, 
which was immortalized from a CF patient with a mutation ΔF508. This mutation accounts 
for 70% of CF patients, and it does not allow CFTR protein to be transported128. Medium 
testing, with 10% fetal calf serum for both cell media, started this characterization and 
incubation of CFBE41o- cells in RPMI THP1-medium led to early cell proliferation, so the 
regular medium was used for the co-culture (fig.21). On microscopy, the viability dye used 
did not correctly stain CFBE41o- cells, which might be due to cell turnover and proliferation 
instead of actual cell death. Even so, macrophages adhered to the transwell already 
containing stable CFBE41o- epithelial layer. 
 Focus on macrophage behavior had shown the movement of these cells and an evident 
change of morphology towards macrophage activation when the co-culture was maintained 
for longer time (36 hours post macrophage seeding, fig . 21C). This could be from cell debris 
of the needed cell turnover on the epithelial layer that would bring influence on the 














Figure 21. Establishment of co-culture CFBE41o- epithelia with THP1-macrophage. A) Medium testing via cell 
growth kinetics of CFBE41o- cells, using a CASY automated cell counter. B) Confocal micrographs showing 
apical and cross-sections of uninfected co-culture. C) Uninfected co-culture after 36h of cell interaction changes 




3.2.1.5. LPS-triggered inflammation on the co-culture  
 Once the 3D co-culture was established investigated, we assessed the potential to 
trigger inflammation with Lipopolysaccharide extract from E. coli (LPS). For that, mono and 
co-cultures were treated with 10µg/ml of LPS in CFBE41o- cell medium and measured the 
followings parameters: cytotoxicity, TEER, and the release of interleukins. 
Figure 22A and B demonstrates that for the timepoint required of analysis (6 hours), 
even though LPS itself is not disrupting the epithelial barrier even after 20h of incubation. 
However, co-culture leads to a decrease in TEER. There are no differences in TEER values 
or cytotoxic levels from the samples.  
By placing an immune cell with an epithelial layer, we can activate this system. This 
activation is the possible start of inflammation. If we consider that drug testing should 
understand the organ’s complexity, the addition of infection and inflammation are essential 
variables to be found on drug efficacy. With the co-culture, we expect to have a higher 
release of cytokines due to cell-cell crosstalking129,130. 
LPS from E. coli at that specific concentration was not able to stimulation CFBE41o-
monoculture on interleukin-8 (IL-8) release (Fig. 22C). However, it stimulated THP-1 to 
release around 2500 pg/mL of IL-8 after 6 hours of exposure. This was then translated to 
contribute to the release of this cytokine from the co-culture, an advantage on modeling of 
excessive inflammation. Interleukin-1β was stimulated with LPS on mono and co-culture, 
although at lower release than expected, showing the need for a full stimulation with the 






Figure 22. LPS stimulation (10µg/mL) on co-culture establishment. A) TEER measurements of 10 LPS 
stimulation on mono and co-cultures after 1, 6 and 20 hours. B) LDH release after 6 hours of LPS stimulation. 








3.2.1.6. Optimization of bacterial growth on cell infection  
 With wild type strain of P. aeruginosa we can monitor bacteria growth alterations, 
however the host-pathogen interaction requires detailed visualization of microbe adherence, 
maturation and possible formation of communities; this work is facilitated with the use of 
fluorescent probes for cell nuclei, cytoplasm, membrane and a constitutively fluorescent 
bacteria (our case using PAO1-GFP). 
 An initial step is to monitor growth via optical density, and figure 23 shows no 
significant differences in PAO1 wild type versus PAO1-GFP during the time interval of the 
proposed infection (1-20 hours). Also, bacteria proliferation was compared via CFU assay, 
and incubation of bacteria alone for 6 or 20 hours did not show differences between the 
strains. 
 
Figure 23. Growth curve and proliferation of P. aeruginosa strains wild type and GFP, respectively, via optical 




 Once defined the balanced growth of the strains, the following work was performed 
only with PAO1-GFP. Following the literature search87,114,118,131, the use of the ratio of 20 
bacteria to 1 cell is the most common adopted multiplicity of infection (MOI).  
Variation of MOI must be assessed beforehand to observe the development of 
infection, but, at that same time, the cell model is alive in the easy-to-work experimental 
window of 1 to 12 hours post-infection. By experimenting with lower MOI’s, we assessed 
these differences and adaptations.  
After 1 hour of bacteria adherence, the bacteria suspension is removed, and the 
infected monoculture model (for initial observations) is incubated for different time points. 
Instead of using the entire sample, we can separate the “type of bacteria” via the ones that did 
not adherence to the suspended ones. Those are then named planktonic for the suspended 
individual bacteria versus biofilm for the adhered ones and lysate for the membrane-
associated and intracellular bacteria. We then proceeded with a stratification of the same 
well/sample: on figure 24A, first wash obtained planktonic bacteria, while the cell lysate was 





Figure 24. CFU versus multiplicity of infection. A) Stratification of 
fractions on an infected CFBE41o- monoculture with P. aeruginosa. B) 
CFU assay from supernatant fraction including planktonic bacteria. C) 




 Figure 24B shows that along 1, 6, or 20h of infection, there is no significant difference 
in CFU growth in between the mentioned fractions. We cannot explain the reason behind the 
lack of variation, but the adaption of bacteria in contact with eukaryotic cells has been looked 
into, and even cytotoxicity is not altered by the increase of P. aeruginosa’s MOI132. 
 An essential step of optimization then includes the reasoning of the ratio around the 
defined multiplicity of infection. Moreover, although we tried 4 variations of the MOI, 
including 10, 1, 0.1, and 0.01 of PAO1 to 1 of CFBE41o- cells, there were no apparent 
differences in cell morphology or bacterial proliferation, as demonstrated on figure 25.  
We adopted MOI 1:1 as this showed a more stable epithelial layer (fig. 25 shows 
micrographs of more intact and few suspension cells) at time point 6 hours post-infection. 
Furthermore, this timepoint is one of our main interests since it allows experimentation of the 
model on the same day. However, in the future, we must pursue a more detailed 
characterization and cell-bacteria interaction, as other information here may lead to cues 




Figure 25. Light microscopy insights into epithelial cell morphology on transwell and variation of the 
multiplicity of infection of P. aeruginosa. Scale bar 10 µm. 
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3.2.1.7. Using fluorescent dyes to uncover P. aeruginosa biofilm formation on top of human 
cells  
 Using light microscopy provides a crude and qualitative visualization of infection and 
epithelial response, so the use of fluorescence in confocal laser scanning microscopy adds 
here the advantage of access to different parts of the epithelial layer thickness, plus the 
possibility to combine images to create a three-dimensional visualization model. 
 A pre-staining protocol can be used with CellTracer® viability dyes, focusing on the 
use of molecules that are only converted inside the cytoplasm of living cells by amino 
esterases. Besides, 4′,6-diamidino-2-phenylindole (DAPI) is a second dye that will help in the 
identification of cell nuclei and extracellular DNA. 
 Not only the epithelial layer can be pre-stained, but also P. aeruginosa. Using this 
combination, we aimed to observe areas of dense bacterial proliferation. With that, in figure 
26A, CFBE41o- cells without infection are shown to be viable on the transwell; that is not the 
case after 4 and 8 hours of infection. Despite the use of the pre-staining method, bacteria have 
a high division rate, which does not attain the dye after many cycles. Even so, the 
visualization of infected wells shows bacteria aggregation surrounding dead cells that still 
maintain intact nuclei (although the nuclei membrane is more fragile-looking after 8 hpi). At 
8 hpi, some of the aggregates present ramifications resembling a polymeric mesh and is 
surrounding by cell debris or extracellular DNA. 
 This architecture further observed in figure 26B where only the fluorescence from 
bacteria is shown; in some, the bacteria signal is visualized inside the dying cells. DNA and 
F-actin are known to provide triggers onto the genetic expression of bacteria to transition 
from planktonic to biofilm133. Furthermore, those polymers can even provide the architecture, 
swarming of P. aeruginosa and the efficient flow during and inside the formation of biofilm.  
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 When F-actin staining is added to the samples (fig. 26C), we observed the needed use 
of this polymer on uninfected cells to provide membrane stability. On infected cells, F-actin 
co-localizes and surrounds bacteria aggregates and in the future, we hope to understand how 
this molecule could be engineering towards antibiofilm therapy. Also, when overlapped with 
transmitted light microscopy, we can understand that i) DAPI staining also marks bacteria 
nuclei and extracellular DNA where the biofilm matrix is present and ii) not all bacteria are 













Figure 26. Fluorescent micrographs of uninfected and infected CFBE41o- epithelial layer and P. aeruginosa MOI 1:20. A) Evolution of infection using pre-stained viability 
dyes. B) Selected bacteria signal to show early biofilm architecture. C) Use of F-actin and overlapping with transmitted light microscopy to show support of the biofilm 
architecture by cell debris and autolytic polymers. N= 2 independent experiments. 
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3.2.2. Co-culture infection 
 To bring the co-culture model on a diseased state of Cystic Fibrosis, the inclusion of 
bacteria is performed with the use of P. aeruginosa (PAO1-GFP).  
As explained above, the infection was executed and six hours after infection, co-
culture and monocultures controls were fixed and membranes were mounted for CLSM. 
Figure 27A shows bacterial aggregates resembling early biofilm are found on top of the 
epithelial layer while this layer has apparent missing cell spots. Those aggregates are 
considered as early biofilm due to its morphology and co-localization of the surroundings by 
DAPI-DNA staining, a characteristic of extracellular DNA used on the biofilm matrix134. 
Interestingly, macrophages can be found both at the basolateral and apical side and that will 
be approached in next sections. 
 When infection takes place for 24 hours, the co-culture is destabilized in which there 
are no epithelial layer and only a small number of macrophages (fig. 27). Nonetheless, 

















Figure 27. Confocal micrographs of co-culture establishment. A) Apical views per channel and cross-section of 
co-culture after 6 hours post-infection with macrophage transmigration (arrow). B) Apical view and cross-
section of co-culture after 24 hours post-infection: the presence of resistant macrophages and formation of 






3.2.3. Macrophage transmigration and bacteria uptake through the transwell membrane and 
epithelial layer 
 To evaluate the combination of THP1-macrophages to the bottom side of a transwell 
membrane, we seeded 200,000 cells in 200µl of cell medium, and then we examined the 
recovery of macrophages onto the transwell after 1 hour of incubation. For each condition, 
the wells were followed for 1, 3, 6 and 18 hours after the macrophage seeding/incubation. We 
then fixed and mounted the membranes and used CLSM to image macrophages on the 
basolateral side.  
We then investigated the kinetics of this migration on conditions of monoculture 
versus macrophages in co-culture with CF epithelial cells. Those observations were followed 
along time using CLSM of fixed samples at 1, 3, and 6 hours post-infection, as shown in 
figure 28. Cross-sections or orthogonal views were placed where the transwell membrane is 
in the middle as a separation of the apical and basolateral compartment. For the co-culture, 
the transwell area is filled with DAPI-stained CFBE41o-, while for monocultures of only 
THP-1 it is blank. At 1 hour, macrophages (red) are observed below the transwell membrane, 
while at 3 hours (and continuously at 6 hours), macrophages can be found in migration down-
up towards the denser load of bacteria or infected CF epithelial layer. Notably, the co-culture 
reveals that is a biological barrier that does not allow bacteria to easily cross the membrane, 
but that selectively will enable macrophages to transmigrate to the air interface. 
To further follow the role of this transmigration, we continued using CLSM to assess 
bacteria uptake by macrophages, as shown in Figure 29. For the macrophages monoculture, 
we used the orthogonal view from the z-stack-created 3D model; this allowed visualization 
inside the cells. For co-cultures, we used cross-sections after identifying the extension of the 
macrophage along the co-culture, either on basolateral side or apical side, depending on the 
time point assessed. Aligned with macrophage transmigration, bacteria uptake was also 
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occurring only after 3 hours post-infection and maintained at 6 hours. However, at 1h of 
macrophage monoculture when the macrophages are still at the basolateral side, bacteria can 
already be seen crossing the membrane to reach the cells, indicating that the macrophages do 
not immediately react and start migration even after bacteria has established at the air 
interface. While on the co-culture, there is the epithelial layer that can act as barrier and it 
communicates with macrophages to start migration; this barrier might prevent the detection 
of bacteria, as observed in fig. 29, 1hour. 
 Transmigration is one of the first actions derived from inflammatory signals135, but we 
expect the modeling with this co-culture would also stimulate the inflammation scenario. On 
figure 30, we observe the kinetics (1, 3, 6, and 20 hours post-infection) of IL-8, IL-6, IL-1β, 
and TNF-α on mono and co-cultures. While P. aeruginosa is clearly a significant stimulus for 
inflammation, the time point of 6 hours is the best point to analyze future possibilities of anti-
inflammatory therapy in the presence of the two cell types here considered. Plus, IL-8 and IL-
1β are released as consequent of the co-culture establishment, while TNF-α is not and 







Figure 28. Kinetics of macrophage transmigration on mono and co-cultures. N= 2 images per sample of 
3 independent experiments. 
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Figure 29. Kinetics of bacteria uptake by transmigrated macrophage on mono and co-cultures. N= 2 




Figure 30. Supernatant results of cytokine 
release. A) Kinetics of uninfected and 
infected mono and co-culture releasing IL-




3.2.4. The pattern of ZO-1 tight junction in CFBE41o- mono or co-culture is expectedly 
disrupted with P. aeruginosa infection 
 Zona occludens is one of the main tight junctions relevant for any epithelial layer, also 
for the lung. The barrier formed by CFBE41o- cultivation is increased before and after co-
culture establishment as observed in fig. 31. However, as expected, bacteria co-cultivation 
disrupts this barrier already after 6 hours of infection. This information can be quantified by 
measuring TEER, as will be shown in section 3.2.2.2. Particular regard must be taken 
towards the localization of ZO-1. At the confocal, one must look across the z-axis on the cell 
model to find the ZO-1, but, at the same time, not to confuse with the transwell signal. Plus, 
specific areas on the basolateral side must be observed to check if the presence of 












Figure 31. Investigation of ZO-1 tight junctions on the establishment of co-culture. A) ZO-1 on uninfected mono and co-culture of CFBE41o-cells. B) ZO-1 on CFBE41o-
monoculture after 6 hours of infection. C) ZO-1 on CFBE41o-+ THP1 co-culture after 6 hours of infection. N= 2 images per sample of `2 independent experiments. 
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3.2.5. Treatment of infected co-culture 
3.2.5.1. Biocompatibility and antibacterial effect of Tobramycin on CFBE41o- cells and P. 
aeruginosa PAO1-GFP  
 The most prescribed aminoglycoside antibiotic in CF disease is tobramycin. We chose 
a range of 0.1 to 1000 µg/mL of tobramycin. The analysis was towards the possibilities of 
dose increase versus antibacterial effect at 50 and 90% of the MIC against P. aeruginosa.
 The high concentration of tobramycin had no cytotoxic effects on CFBE41o- cells 
after 24 hours of incubation (fig. 32A and B). Analyzing the kinetics of a tobramycin range of 
concentrations, 1 to 4 µg/mL of tobramycin allows bacterial proliferation on the first 1 to 8 
hours of incubation (fig. 32C), but focusing on 24 hours of incubation 50% of bacterial 
growth was contained using 6 µg/mL of tobramycin, which, then, was the adopted 











Figure 32. The activity of tobramycin on P. aeruginosa PAO1-GFP and biocompatibility on CFBE41o- cells. A) 
MTT assay for the viability of CFBE41o- cells within a range of 0.1 – 1000 µg/mL (24h). B) LDH release for 
cytotoxicity of CFBE41o- cells within a range of 0.1 – 1000 µg/mL (24h). C) Kinetics of antibacterial activity 
of tobramycin (1-250 µg/mL) on PAO1. D) Antibacterial activity of tobramycin after 24h of interaction with 







3.2.5.2. Cytotoxicity and TEER values on the infected co-culture 
 Markedly, the induction of cytotoxicity is lower than expected for the bacterial 
challenge on the release of lactate dehydrogenase (fig. 33A), and in none of the time points 
analyzed, the LDH levels were above 40%.  
In 1h, there is about 20% LDH release for CFBE monoculture and co-culture with 
infection. However, in 6h, non-infected CF monoculture and on the co-culture there is a 
release of LDH. This result is also seen in another report in which PMA is used as activation 
agents for THP-1 macrophages in co-cultures136.  
While at 20 hours post-infection, the observed cell death in other methods is not 
correlated to the alterations in LDH release, unless for non-infected co-culture. Here the 
literature reveals that variables as pH, media with sodium pyruvate, or production of certain 
acids might cause problems on the detection of LDH137. We recommend to this issue to be 
further investigated, however we focused on the timepoint of 6 hours to combine results with 
other important varaibles peaking at this time. 
Nonetheless, co-culture conditions at 6 hpi show 20% of LDH for infected samples 
and a complete statistically significant decrease after tobramycin treatment, which is not 
observed for epithelia monoculture conditions.  
The epithelial barrier integrity was checked via TEER, in co-cultures and 
monocultures (Figure 33B). After 6 and 20 hours, no difference was observed between the 
TEER of CFBE41o- in uninfected monoculture or co-culture. The infection, however, 
disrupted the barrier, as observed by the drop in the TEER. Nevertheless, once the cultures 
were treated with Tobramycin, the epithelial barrier integrity was restored, as observed by 
higher TEER values. 
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However, at our main timepoint of 6 hours, only on co-culture samples, we observed 
barrier recovery on infected tobramycin-treated cells (6hpi) and that this recovery is as high 
as it was for the uninfected cells. These results should be further analyzed on the regulation 











Figure 33. Biocompatibility of co-culture, 
infection and tobramycin treatment. A) 
Kinetics of LDH release assay on mono 
and co-cultures, treated and untreated. B) 
TEER measurements at 6 and 20 hpi on 




3.2.5.3. Co-culture decreases CFU while tobramycin masks biofilm formation 
Our previous results showed that macrophages migrated from basolateral to the apical 
side of the transwell, crossing the epithelial layer and uptaking P. aeruginosa (Fig 29). 
Confocal microscopy shows that bacteria aggregates are still formed even with the presence 
of macrophages on top of the CF epithelia (Fig 34).  
Figures 35 A and B shows differential growth of adhered/internalized bacteria at 6 hpi 
grown in presence versus absence of human cells, but no difference in between the cell types 
used as substrate. Importantly, in tobramycin-treated samples for 6h, no bacteria colony was 
observed, although we have seen bacteria by the confocal microscopy (fig. 34). However, at 
the 20 hpi time point, treated samples now present cultivable P. aeruginosa on agar plates 
(Figure 35 D and E) (probably because there is no more pressure of host cells as observed on 
earlier confocal micrographs). 
To further evaluate the results of tobramycin, we re-analyzed CFU 6 hpi 
(adherent/internalized bacteria). “Tobramycin killing” is then defined as: 
Tob killing (log10) = log infected not treated – log infected Tobramycin treated 
Figure 35C shows the results comparing tobramycin killing 6hpi when PAO1 is alone 
and when PAO1 is on the co-culture. An approximate 1 log is the statistical difference 
between these groups. However, the same does not occur when the analysis is at 20 hpi. 
Although the presence of human cells influences tobramycin to have an enhanced 
efficacy138, our results showed bacteria with cells forces a decreased antibiotic efficacy. 
Further studies are required to check if the presence of cells influences on bacterial rate of 





Figure 34. Confocal 
micrographs of mono and 
co-cultures with and 
without treatment with 
tobramycin 6µg/mL. From 
the acquisition of zeta 
stacks from the apical side 
only of the samples, DNA 
is stained by DAPI (blue), 
macrophages (red) and P. 
aeruginosa (green). N= 2 
images per sample of 3 
independent experiments. 





Figure 35. Bacteria proliferation on 
mono and co-culture at 6 and 20 hours 
post-infection. A) Colony-forming 
units (CFU) of adherent/internalized 
bacteria after 6 with tobramycin 
6µg/mL treatment. B) CFU of 
extracellular bacteria after 6 with 
tobramycin 6µg/mL treatment. C) 
Tobramycin killing effects compared 
on bacteria alone versus bacteria on 
top of co-culture at 6h of infection. D) 
CFU of adherent/internalized bacteria 
after 20 with tobramycin 6µg/mL 
treatment. E) CFU of extracellular 
bacteria after 20 with tobramycin 
6µg/mL treatment. F) Tobramycin 
killing effects compared on bacteria 
alone versus bacteria on top of co-




3.2.5.4. Co-culture conditions increase immunological response without alterations from 
tobramycin treatment 
 To further evaluate the inflammatory response in our co-culture model, we checked 
the inflammatory response by looking at a panel of inflammatory cytokines (Figure 36). 
These are characterized as the following: 
1. Pro-inflammatory signaling: 
IL-6, IL-11, IL-1α, IL-18, IL-8, TNF-α, IL-1β and IFN-γ 
2. Anti-inflammatory signaling: 
IL-12p40, IL-23, IL-27, IL-10 
3. Adaptive immunity: 
IL-15, GM-CSF, IL-21, TSLP 
From those  16 cytokines tested, we detected 6 cytokines that showed a higher release 
in the  co-culture (IL-1α, IL-8, IL-12p40, IL-18, IL-23, TNF-α)  and other 10 that did not 
show significative release (GM-CSF, IFN-γ, IL-1β, IL-6, IL-10, IL-11, IL-15, IL-21, IL-27, 
TSLP). Indeed these last 10 cytokines were previously released by the uninfected co-culture, 
which could account for their low secretion level after the infection.  
Notably, treatment with tobramycin as the established conditions did not reduce the 
inflammation. Evaluating IL-8, IL-6, and IL-1β (fig. 30) revealed cooperation of epithelia and 
macrophages when in co-culture condition, providing an inflammation scenario reflecting the 
clinical correlation of P. aeruginosa in the cystic fibrosis lung environment 58,139.  
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Despite the seen moderate inhibition activity in the literature140, the use of tobramycin 
(blue bars) has shown no cytokines decrease, except for IL-6 on the monoculture of 















Figure 36. Supernatant 
results of cytokine 
release. Cytokine panel 
via flow cytometry of 
GM-CSF, IFN-γ, IL-
1α, IL-1β, IL-6, IL-8, 
IL-10, IL-11, IL-12p40, 
IL-15, IL-18, IL-21, 
IL-23, IL-27, TNF-α 
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3.2.5.5. Virulence factors can also be detected during co-culture conditions  
Pyocyanin and pyoverdine are quorum-sensing molecules from the Pseudomonas 
quinolone signal (PQS) system141. Usually, these molecules are detected in P. aeruginosa 
biofilm growing on plastic substrate142,143. We then asked whether these molecules could also 
be detected in our co-culture model, which would be necessary for drug testing aiming to 
inhibit biofilm communication.  
By using our system, with cells seeded on transwell, we could not detect pyocyanin or 
pyoverdine.  Therefore we adapted our co-culture model to the 24-well microplates, keeping 
the same cell density. These changes allowed us to measure those quorum-sensing molecules.   
As seen in Figure 37, pyocyanin and pyoverdine can also be quantified when human 
cells are present, but not on time points as early as 6 hours post-infection (Figure 37A). 
Although the levels do not change in between the different types of cells versus bacteria 
alone, tobramycin reduces pyocyanin and pyoverdine levels that could prevent biofilm 
formation because of bacteria-killing (Figure 37B, C).  We used a synthetic PqsR inhibitor, 











Figure 37. Measurement of virulence factors on mono and co-cultures transferring from the transwell to the flat plate model. A) Kinetics of the detection of pyocyanin on 
mono and co-cultures. B).Pyocyanin results of PA-14 infected co-cultures treated with tobramycin (6µg/mL) and pathoblocker HIPS1121 (1µM). C) Pyoverdine results of 




In this investigation, we used the interaction of P. aeruginosa bacteria against abiotic 
and selective biotic substrates that could mimic the CF bronchial airways. On establishing a 
model of CF bronchial epithelia, macrophages, and P. aeruginosa we reveal alterations on 
host response and bacteria adaptation on top of human cells. On mimicking the bronchial 
area, we used a model of macrophage adherence based on the need for immune cells to 
migrate from the bloodstream towards the air interface to reach the bacteria infection. 
The immune system is present during the evolution of bacterial growth, and the 
bronchial region of the lung is in contact with bacteria via the air interface during breathing. 
In the proceedings of acute infection, the epithelial layer senses danger signals of the bacteria 
and starts the recruitment of the immune cells22. For the specific case of the upper airways, 
this recruitment requires the transmigration of immune cells from the bloodstream, passing 
through several cell layers until reaching the air interface where the infection is taking 
place145. The proposed model involves a human Cystic Fibrosis bronchial epithelial cells, 
human macrophages, and P. aeruginosa. With this set, it is possible to evaluate i) the 
formation of a confluent lung epithelial layer, 2) the macrophage transmigration mimicked 
from basolateral to apical side of the Transwell® membrane, and 3) development of 
planktonic P. aeruginosa into an early biofilm. 
Approaching drug testing, most reports include the use of animals and, even though 
the cost is high, in vivo research is still a majority. That said, by using animals, we fail to 
characterize details and steps during therapy response or other processes more related to cell 
behavior, including chronicity of infections. We opted for Cystic Fibrosis Bronchial 
Epithelial (CFBE41o-) cell line as a diseased model for the airways. This cell line is known 
to maintain an essential mutation associated with CF, the ΔF508. Moreover, more 
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characteristics are associated with CFBE41o-, as chloride transport impairment with high 
transepithelial resistance of an epithelial barrier formation 146.  
The infection of CFBE41o- using P. aeruginosa has been described, mainly using a 
flow-cell chamber model with supplementation with arginine on the cell media composition 
to improve epithelial cell survival and support biofilm formation 147. There, it was already 
observed that bacteria grown on top of cells were 25 times more resistant than bacteria alone 
and that the mutation from the CF cells increases the release of iron, consequently helping 
biofilm formation. Besides infection, the addition of immune cells has been used on bronchial 
cells. Ding et al. 104 used mouse Lewis lung carcinoma cells on Transwell® in combination 
with macrophages on the basolateral side and infected with Staphylococcus aureus, another 
critical pathogen of chronic infection in CF patients. Their method granted the observation of 
different macrophage movements (including Transwell®-cell transmigration) and even 
bacterial phagocytosis. 
Our studies build a new model using only human cells grown at the air-liquid 
interface, in a Transwell® model that can be scaled-up for more than one well, if compared to 
a flow-chamber. The inclusion of THP-1 differentiated macrophages is an advantage for 
using a human immortalized cell line, instead of depending on the reproducibility and 
obtainment of primary cells from donors. By adding these macrophages on the basolateral 
side of a Transwell® insert, we could observe these macrophages not only create protrusions 
to reach the apical side, but also to follow transmigration. 
With our results, we obtained a model that includes epithelia, macrophages, and 
bacteria, as seen in Figure 1, and three main accomplishments: i) observation of early biofilm 
formation after 6 hours, ii) macrophage transmigration, and iii)maintenance of epithelial cell 
survival. The next steps include using confocal microscopy to understand the development of 
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these 3 variables when into the co-culture. Importantly, our studies on macrophage 
transmigration show that the epithelia for a transwell model represents a natural barrier for 
bacteria (fig. 24), but instead a selectively permeable barrier to the diffusion of inflammatory 
mediators and its consequent stimulation of macrophage transmigration. 
Notably, comparing treated samples and the rest of bacteria growth (tobramycin 
killing) on the only PAO1 versus PAO1 on co-culture, bacteria on top of cells react less to 
tobramycin treatment (Fig. 4C). Although the presence of human cells influences tobramycin 
on an enhanced efficacy138, our results showed that using tobramycin as treatment responds 
differently when comparing bacteria alone versus bacteria in the presence of cells. 
Marquis-Moreau et al.147 observed resistant bacteria onto human cell growth; 
however, their model approaches treatment aimed for biofilm eradication, which means there 
was biofilm growth for 6h and then following tobramycin treatment. On our data, we show 
results on treatment performed at 1 hour after the bacterial adherence, focusing on the 
treatment of acute infection and possibly influencing further experiments on re-infection. 
 An adhered/internalized fraction, after human cell lysis and the removal of planktonic 
bacteria, is the most important on what has remained with or without treatment. Actually, the 
evaluation of different fractions will give you different answers accordingly: when you look 
at the bacteria that are adhered/internalized you are considering the population that remains 
attached to the bronchial tissue, as it is in vivo. In this case, the killing (20 hpi), after 
tobramycin treatment, is 10x times higher on bacteria alone than bacteria on top of cells.  
The conclusion from this data must come with the thought that usually drug testing is 
performed on bacteria alone, hence the MIC, MBIC (biofilm inhibition), or MBEC (biofilm 
eradication) assay. When using just bacteria on abiotic surfaces, there is more killing, a 
finding that does not occur on bacteria grown on top of human cells, on the mimicking of 
102 
 
what happens in vivo. An overestimation of drug/antibiotic efficacy then occurs on the 
simplification of drug testing, either for planktonic bacteria, but even worse in the case of 
biofilm bacteria. 
Pyocyanin and pyoverdine are quorum sensing-dependent PA-exclusive secondary 
metabolite regulated by the Pseudomonas quinolone signal quorum-sensing system (PQS-
QS)82,148. In a recent report, only pyoverdine and not pyocyanin were recovered from the 
growth conditions applied to the co-cultivation of bacteria and human cells118.  
With our conditions, not only these phenazines were recovered on wells with bacteria 
alone, but also both pyoverdine and pyocyanin were recovered on bacteria that used the 
human cells as substrate. For us, the recovery of these compounds was only possible at 20 
hpi, but not at 6 hpi (fig. 37A), which might be associated with the MOI variation.  
In a similar fashion to Orazi and O’Toole118, we also found there was a small 
difference of pyoverdine release when comparing bacteria on plastic versus on top of cells 
(fig. 37C). And, the same trend is observed for untreated samples on the version of pyocyanin 
(fig. 37B). 
Although plastic versus cell did not show differences, this is a positive outcome for 
drug screening, in which at least for those compounds the interaction cell-bacteria may not be 
disturbed by differential cultivation. 
 The testing of tobramycin and HIPS1121, quorum-sensing inhibitor, shows the 
usefulness of the method and possibility of future combination of indicators that analyze 
bacteria and cells at the same time. The use of tobramycin has decreased levels of pyocyanin 
and pyoverdine. However, the reduction in pyocyanin was 75%, which means there will still 
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be a remaining level of pyocyanin to influence biofilm formation. If that would be enough to 
promote biofilm growth and other bacterial modifications should be further investigated. 
HIPS1121 is a pathoblocker in a concept that biofilm control not always needs to be 
understood through the reduction of bacterial proliferation but on the decrease of virulence 
factors. This compound was confirmed to completely extinguish the release of pyocyanin 
since it influences directly on the PQS system, but not on the production of pyoverdine. 
With differential bacteria growth, also host response can be altered. Observing figure 
6, sixteen cytokines have been analyzed after infection, but even after tobramycin treatment. 
At first glance, we see success on the co-culture to provide the mimicking scenario 
resembling CF disease, especially for cytokines involved with pro-inflammation and 
neutrophil recruitment, linked with type-I interferon response. The immediate advantage 
observed is the maintenance of the levels during co-culture conditions within the majority of 
the detected cytokines, translating the inflammation scenario, but now with the combined cell 
types. 
In fact, John et al149 demonstrated with immunochemical histology assays that CF 
bronchial epithelial cells can show significantly reduced expression of TLR-4. This would 
directly regulate the release of IL-8 and impair local innate immunity, especially under the 
stimulation with P. aeruginosa. This sparkled that CFTR mutations from CF might be 
responsible for a state of hyper inflammation seen in patients. Although some work150 has 
been done to clarify this, there is a limited understanding of the cytokine network during CF. 
The cytokines analyzed are limited central regulator cytokines like IL-8 and TNF-α, which 
can present in numerous secondary messenger cytokines affecting different aspects of innate 
and adaptative immunity. 
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We were expecting i) PA to be a potent stimulus for cytokine release and ii) the 
reduction on bacteria growth upon tobramycin treatment would rescue the inflammation. 
Because of CF alterations on the airways, this remodeling induces bronchiectasis and 
neutrophilic recruitment, which are very early characteristics of CF; plus, this is observed in a 
controversial state of absence of infection related to a combination of necrosis, hypoxia, and 
activation of the inflammasome via IL-1α151. On that note, Fig. 6 grey bars show cytokine 
release without infection during the set-up of the co-culture, which can be associated with the 
formation of the epithelial layer and aging, plus the transition/activation of THP1 monocytes 
to macrophages.  
Although we did not measure cytokines versus multiplicity of PA infection, the 
observed bacteria growth, release of virulence factors and early biofilm would serve as a 
stimulus for a hyper inflammation state. Indeed, the fact that CFTR is a pattern recognition 
receptor for microbial sensing and the combination with the mutations related CF what 
impairs a strong inflammatory response53. This duality is demonstrated when 6 (IL-1α, IL-8, 
IL-12p40, IL-18, IL-23, TNF-α) out the 14 detected cytokines could be increased with P. 
aeruginosa challenge. 
This network has been producing new hopes for therapy, as anti-TNF antibodies could 
potentially reduce inflammation and tissue damage152; although in practice, there is more 
concern on its medicine safety and the limiting inflammation to disarm immunity from 
opportunistic infections153. The opportunity can now be directed from other cytokines as 
future targets. 
IL-1β is dependent on monocytes, in our case, from the interaction of CF epithelia and 
macrophages. Results of Figure 6 shows there is cooperation when CF epithelia and 
macrophages are combined into the co-culture. Furthermore, this cooperation can be 
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explained precisely because CF epithelia do not produce IL-1β, but it expresses IL-1 type I 
receptor (IL-1RI), IL-1 receptor accessory protein (IL-1RAcP), and IL-1 receptor antagonist 
(IL-1Ra) 154. 
Bonfield et al.154 describe alterations in CF human lungs. They measure the cytokines 
IL-10 (anti-inflammatory) and the pro-inflammatory IL-8 and IL-6, showing that CF patients 
do not release IL-10 and have higher levels of IL-8 and IL-6.  
For that, we continue the exploitation of our co-culture model by measuring the pro-
inflammatory cytokine IL-6 that activates the adaptive immunity through the maturation of T 
and B-lymphocytes155, so the connection between the innate and adaptive immunity gains 
contributions from both the CF epithelia and macrophages; nonetheless, the co-culture 
maintains same levels of release. In general, the key messages by analyzing IL-8, IL-1β and 
IL-6 are the contributions of both cell types (in co-culture) for different cytokines. 
Despite lower levels of TNF-α and IL-1β (central macrophage-releasing cytokines), 
the co-culture still secrete secondary cytokines from the TLR-4 domain, like IL-8 and IL-
6.GM-CSF deficiency can impair the function of alveolar macrophages in a knock-out mice 
model of infection156, while the neutralization of IL-27 in septic mice significantly improved 
survival and clearance of bacteria from the lungs of septic mice infected with P 
aeruginosa157. Both of those functions to be critical points of the development of sepsis. 
As the second line of defense, adaptive immunity promotes the clonal expansion of 
lymphocytes and IL-6 is present to differentiate and mediate survival of T cells, as CD4+ as 
long-lived memory T cells158. Still, in type 2 immunity, a similar role has been associated 
with TSLP as an alarmin derived from tissue damage; this cytokine is only known to play a 
role in helminth infection and asthma159, but its involvement in pro-fibrosis should also be 
investigated for the pathological scenario of CF. As cascades of cytokines are altered during 
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diseases, other mechanisms to salvage immune cells can be achieved, for instance, as IL-15 
therapy was found to increase Bcl2, an antiapoptotic protein, and to avoid death of crucial 
cells and NK and CD8+ T cells during sepsis160.  
While most cytokines were not affected by tobramycin treatment, we evident the trend 
of control of cytokines as IL-8 that would prevent neutrophil recruitment and the 
maintenance of IL-10 on the promotion of inflammation inhibition. In fact, the use of 
cytokines as therapy, at least in our model, can be further investigated as IL-11 has been 
shown to increase survival rate of a sepsis model, with the advantages of controlling 
inflammation via the production of TIMP-1161, plus the known IL-10 which via inhibition of 
MHC class II and several other cytokines is considered the main anti-inflammatory 
cytokine162. However, even IL-10 as a master regulator of infection can be misused since 
early neutrophil and macrophage recruitment are instrumental developments to clear bacteria 
from the lungs163. 
The response to tobramycin is crucial to establish a CF model, especially on 
tobramycin being effective on inhibiting P. aeruginosa and even on biofilm mode of growth 
164,165. Our result shows no significant alteration of cytokine levels with treatment, what 
corroborates the incentive of adjuvant drugs on the control of inflammation, but supports a 
comprehensive investigation of antibiotic efficacy on adapted bacteria to correlated lung 
environments.  
We must consider that the concentration used here is in the MIC range; despite that, it 
was not possible to eliminate all bacteria as observed by confocal microscopy. This could 
justify the non-antiinflammatory characteristic of tobramycin as a consequence of remaining 
bacteria to subsequently continue the induction of inflammation.  
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It is then recommended to analyze differential bacteria growth versus host response, 
based on the comparison towards increased efficacy of antibiotics on bacteria grown on 
plastic than on 3D cultures 138 and on the inefficacy of this class of drugs on precisely 
controlling the associated inflammation166. 
Some limitations can be pointed out related to the use of CLSM on the identification 
of bacteria uptake, as this does not show an individualized bacterium that could ease the 
quantification, and we recommend a follow-up study with techniques as flow cytometer and 
super-resolution microscopy. Limitations of this co-culture are related to the options we make 
when designing the complexity of the system. Ongoing improvement of the system would 
include the cultivation of biofilm on top of human cells for a period in which there is a 
mature biofilm with completely formed extracellular matrix and persister bacteria. A further 
addition would be to include mucus to investigate the effect of its changed rheology under the 
conditions of Cystic Fibrosis. 
In conclusion, we provided a new platform for the analysis of bacterial growth 
(including P. aeruginosa) to create an environment that is particular to the bronchial airways 
with the incentive of macrophages transmigration. This creates a model that shows an 
epithelial integer layer as a permeably selective barrier, and it contributes to the 
understanding of how a close-related model can provide differential insights on antibiotic 




Chapter 2: Future applications for the co-culture: HL-60 as neutrophil-like cell and its 











 On CF, excessive inflammation is characterized by the infiltration of airways with 
neutrophils that fail to prevent extreme infection from the predominant microbes as P. 
aeruginosa167. This failure could be related to the defects on CFTR protein as well as the 
effects seen on the epithelia, mostly because the control of apoptosis on CF neutrophils is 
altered.168 Nonetheless, one of the main issues with early neutrophil is the excess of oxidative 
stress; a strategy that is supposed to help kill bacteria but turns to injury the lung.169 
 Non-apoptotic neutrophils bring a negative correlation to lung function, and it 
promotes decline during CF disease170. However the prevention of neutrophil to die and 
release its contents might be inevitable. 
 The release of neutrophil content is known as respiratory burst, which in CF the 
impairment of this process will influence the degree of bacterial phagocytosis171. What occurs 
is that the frustrated phagocytosis and increased apoptosis of neutrophils overwhelm the lung 
with increased ROS and proteases. The effects of this increase are observed when pattern 
recognition receptors and opsonophagocytic receptors are cleaved, impairing the proper 
function of neutrophils172. 
If bacteria is uptaken by neutrophils, there is the formation of azurophilic granules 
containing antimicrobial molecules. If there is no phagocytosis, the neutrophil starts its 
programmed death. The release of its content counts with the last strategy for bacterial 
trapping: neutrophil extracellular traps (NETs)173. Some of the strategy and neutrophil 
reactions can be seen in figure 38. 
 Neutrophils are migratory cells that, after chemical signal move towards the bacterial 
targets (chemotaxis) and this is one of the bases of the innate immune system, for instance, in 
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wound healing.168 For pursuing bacteria, neutrophils seek different gradients of formylated 
peptide as N-Formylmethionyl-leucyl-phenylalanine (fMLP) and these molecules together 
with LPS will stimulate e TLR4 and the IKKβ-IқBα signaling pathways to induce 
inflammation.174 
 In vitro, primary neutrophils are not easy-to-cultivate cells, and their lifetime after 
blood extraction is from 6 to 8 hours.175 So, immortalized cell lines are the stable option for 
the modeling disease and cell interaction. HL-60 cells are human caucasian promyelocytic 
leukemia cell line and several reports have accomplished to use this cell as model for 
neutrophils176–178. 
 Chu et al179 reported that bovine serum albumin nanoparticles could be fed to 
neutrophils to hitchhike the activated cells and cross the endothelial barrier from the 
bloodstream towards the tissue. By loading those nanoparticles with an NF-қB inhibitor or 
with cefoperazone acid to hitchhike on neutrophils, those loaded-activated cells were used as 
treatment on in vivo of LPS inflammation and P. aeruginosa infection, providing anti-
inflammatory and antiinfective activity. 
 This section aims to exploring the choices of differentiation agents of HL-60 in 
between all-trans retinoic acid (ATRA), calcitriol od dimethylsulphoxide (DMSO). When 
defined the agent, we characterized the differentiated HL-60 towards neutrophil functions and 
markers.  
These cells were used to initially confirm the uptake of BSA nanoparticles and in the 
future, could be used to screen the kinetics and material of nanoparticle towards drug 
delivery. Moreover, neutrophils could be integrated into the 3D co-culture model87 previously 




Figure 38. Interactions between polymorphonuclear neutrophil (PMNs) and Pseudomonas aeruginosa in CF 




2. Material and methods 
2.1. HL-60 cultivation and differentiation agents 
 Promyeloblast cell line HL-60 (ATCC® CCL-240™) derived from a 36-year-old 
Caucasian female with acute promyelocytic leukemia was grown from passage 16-40 in 
RPMI medium with 20% FCS. The cells were split g every 2-3 days and seeded at 106 
cells/mL in a T75 cell culture flask. For differentiation, HL-60 (100,000 cells/ml) was seeded 
on a T75 per flask. Different differentiation agents were dissolved in RPMI medium and 
incubated in the HL-60 cells: 1µM all-trans retinoic acid (ATRA, ≥98% (HPLC), powder, 
Sigma, Germany), 1µM calcitriol (1,25-dihydroxyvitamin D3, Biomol, Germany), 1,25% 
DMSO (HPLC graded, Sigma, Germany) or as negative control of differentiation with 0.1% 
ethanol.  
Cells were either differentiated on flask or microplates for 4 to 9 days in the RPMI 
medium. If using 12-well microplates (Greiner, Germany), we previously coated coverslips 
of 12mm with poly-L-lysine (0.1 mg/mL) for 1 hour and after cleaned by 5 washes of dH2O, 
ultra-pure water, absolute ethanol, and 70% ethanol. Then place the coated coverslips inside 
the microplates and left for drying for 2 hours under the sterile flow bench. Differentiated 
cells on microplates or coverslips were stimulated with PMA 100nM for 30 minutes before 
characterization assays. 
2.2. Nitroblue tetrazolium (NBT) assay of differentiated HL-60 
 In order to determine the intracellular level of the superoxide anion (O2
-) for 
phagocytic cells, we used the NBT assay. This test is important for neutrophil 




A method from Hirako et al180 was adapted and PMA-stimulated HL-60 in 12-well 
microplates were incubated with 200µL of 2mg/mL of Nitroblue tetrazolium chloride 
(Sigma, Germany) then incubate at 37°C for 30 minutes. After labeling, each sample was 
focused on the search for intracellular blue-black formazan deposits and images were taken 
with the light microscope. Cells were incubated with 100% DMSO for 15 minutes and 
absorbance was measured at 550nm. 
2.3. HL-60 nuclei morphology by DAPI staining 
 Nuclei staining was performed after fixation of PMA-stimulated HL-60 in coverslips 
using 3% of paraformaldehyde in PBS for 1 hour at room temperature (RT). Then 
sfluorescent cells were observed at the CLSM and 50 cells were counted for the percentage of 
altered nuclei morphology towards bi or tri-lobation. 
2.4. Oxidation of 2',7'-dichlorofluorescein-diacetate (DCFH-DA) on differentiated HL-
60 
 A second method to measure intracellular oxidative stress is via the detection of 
intracellular H2O2. Although an indirect measurement of H2O2, DCFH carboxylate anion 
retains the DCFDH-DA probe, and after oxidation, a fluorescent DCF is formed. 
The method from Rastogi et al181 was adapted, and PMA-stimulated HL-60 in 12-well 
microplates were incubated with 100µM of DCF-DA (Biomol, Germany) for 30 minutes at 
37°C. Hydrogen peroxide 1mM was used as a positive control, and fluorescence was 
measured at excitation 465 and emission 535nm. 
2.5. Flow cytometric for the detection of CD11b and BSA particle uptake 
 Using CD11b as a marker for activated neutrophils182, we measured this surface 
marker on PMA-stimulated HL-60. Briefly, cells were trypsinized from cell culture T75 
114 
 
flasks as mentioned and centrifuged (220 G for 5 minutes), then resuspended in FACS buffer 
(PBS + 2% FCS) and transferred to glass tube for flow cytometry.  
Cell suspension was incubated with 10µg/mL of purified human IgG (Sigma, 
Germany) for 15 minutes at room temperature, centrifuged and then stained with 2.5µg/mL 
of FITC/CD11b (FITC anti-mouse/human CD11b Antibody, Biolegend, USA) for 30 minutes 
at 4°C. Cells were centrifuged, resuspended in FACS buffer and used for flow cytometry. 
This was performed using a BD LSRFortessaTM (BD Biosciences, Heidelberg, Germany) 
using BD FACSDiva™ Software v8.0.1. Forward (FSC) and side scatter (SSC) were defined 
for live cells, using a non-stained control. From “living cell” populations (determined by cell 
granularity and size, green fluorescence data (excitation 488 nm, filter: 530/30) were 
collected on a minimum of 10,000 events (cells) per sample. 
2.6. Detection of neutrophil extracellular traps among the differentiated HL-60 
Differentiated and PMA-stimulated HL-60 were grown on 12-well microplates and 
poly-L-lysine coverslips. Then 5 µM Sytox Green (SYTOX™ Green Nucleic Acid Stain - 
5mM Solution in DMSO) was used as a marker of extracellular DNA, which is the main 
component of the released neutrophil extracellular traps (NETs). Those traps are a response 
to microbes and a final attempt from the neutrophils to, at the same time, trap pathogens and 
release antimicrobial peptides as elastase and cathepsinB183. Cells were PFA-fixed, DAPI-
stained, and mounted on microscope slides for confocal microscopy. On the confocal, NETs 
can be observed as an explosion of extracellular DNA associated with cell nuclei. 
2.7. Production of bovine serum albumin (BSA) liposomes: characterization by dynamic 
light scattering and scanning electron microscopy 
Particles were prepared according to Yu et al184 with modifications. Bovine serum 
albumin (Sigma, Germany) was diluted in PBS and a 20mg/ml solution was prepared on 
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Erlenmeyer. Ethanol (an equivalent to 3.5 the BSA solution volume) was added at slow rate. 
For cross-linking, 0.2 % glutaraldehyde was added and the suspension was incubated on a 
magnetic stirrer (180 rpm/minute) for 18hours. After, particles were stained with rhodamine-
labeled Ricinus communis Agglutinin I (2mg/ml for 2 hours, Vector Laboratories, Inc., 
Burlingame, CA, USA) and its physicochemical characteristics were measured with dynamic 
light scattering for size, polydispersity index, and zeta potential185. Or albumin concentration 
after particle production was measured using the bicinchoninic acid assay (Roche, Germany). 
The morphological appearance of all nanoparticles was visualized using two different 
microscopical methods, including conventional Scanning Electron Microscopy (SEM, EVO 
HD15, Zeiss, Germany). For SEM visualization, liposomes were diluted in Milli-Q water and 
2µL of the particle suspension was placed on the SEM copper grid. This grid has been 
previously coated with a carbon disc layered on top with pieces of alcohol-treated silica 
wafer. The drops of liposome suspension were dried and the gold-sputtered before 
visualization. 
 For nanoparticle uptake, cells were grown, differentiated and PMA-stimulated on 
poly-L-lysine coverslips. After that 10, 50 or 135 µg/mL of BSA nanoparticles were 
delivered to coverslip-adhered cells as suspensions on HL-60 cell medium for 2 or 24 hours 
and incubated at 37C, 5% CO2.. Nanoparticle suspension was removed, twice PBS-washed 
then coverslips were stained for anti-CD11b-FITC (Biolegend)  and fixed with 3% PFA (30 
min) for confocal microscopy. For flow cytometry, suspended cells were incubated in test 
tubes with nanoparticles in FACS buffer (PBS + 1% FBS), after timepoints tubes were 
centrifuged (2580 g) for 4 min and resuspended with staining solution in FACS buffer for 1 
hour in the dark. Another round of centrifugation was performed to removed staining, then 
cells were re-suspended on FACS buffer, maintained in ice for subsequent analysis on flow 
cytometer (BD Biosciences) and analyzed using the FlowJo software. 
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2.8. Confocal microscopy 
Cells were imaged using confocal laser scanning microscopy (CLSM, Leica TCS SP 
8; Leica, Mannheim, Germany). Analysis of obtained images was performed using LAS X 
software (Leica Application Suite X; Leica, Mannheim, Germany). 
3. Results 
3.1. Initial characterization of HL-60 on differentiation agents towards the functional 
capacity as neutrophil-like cells 
 After 4, 5, 6 and 7 days of incubation with differentiation agents, HL-60 cells were 
quantified and its viability was assessed. Because we used a CASY automatic counter (Roche 
Diagnostics International, USA), this equipment uses the application of electrical current 
against individual cells in a microfluidic system. This technology then considers viable cells 
as electrical insulators, so dead cells no longer present as an electrical barrier. This can be 
measured and together with a threshold for cell debris, cell size and viability can be 
obtained.186 
 We incubated HL-60 with all differentiation agents for 4-7 days and checked the cell 
viability and cell number (Figure 39A, B). The treatment with all agents did not induce cell 
toxicity or stop cell proliferation, except for DMSO (Figure 39B). It is known that the 
treatment with 1.2% DMSO for 72 hours has down-regulated the suppression of apoptosis-
related to the expression of Bcl-2 gene187, which might explain the decrease in cell 
proliferation observed in our results. Even so cell proliferation has been reduced, there was 




Figure 39. Initial characterization of HL-60 on differentiation agents towards the functional capacity as 
neutrophil-like cells. A) Cell viability via size/granularity for 4, 5, 6 and 7 days of stimulation.  B) Cell growth 
number via automatic counter for 4, 5, 6 and 7 days of stimulation. Ethanol samples as non-stimulated controls. 
N=2 experiments. 
 
 If the cells are growing while differentiating, we used the first assay to assess the 
functionality of these neutrophil-like cells. Nitroblue tetrazolium (NBT) provides an insight 
into the activation of cells towards the use of NADH oxidase to reduce NBT into formazan 
crystals.188 On figure 38C, light micrographs of differentiated PMA-stimulated HL-60 show 
the presence cell filled with formazan purple-black crystals. Compared to non-stimulated HL-
60, the cells that activated its NADH oxidase were DMSOHL-60 after 6 days of exposure. 
 
Figure 40. Quantification of positive cells for the nitroblue tetrazolium assay: differentiated HL-60 and the 
correspondent light micrographs. N= 3 wells per condition on 2 experiments. 
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 Neutrophils can have 3 to 5 lobes as nuclei and this segmentation has been known to 
facilitate i) intranuclear chromatin organization and ii) dynamic shaping of the nuclei when 
negotiating to pass through narrow capillaries, transmigrating across the vessel wall and 
passage through tight tissue spaces189. Promyelocytic cells as HL-60 have spherical nuclei 
and the process of lobation can then indicate the commitment towards neutrophil 
differentiation. 
For a straightforward assessment of nuclei morphology, HL-60 was observed after 
DAPI staining and, on figure 38D, nuclei are distinguished in all agents tests, however 
quantification the ratio of altered nuclei, it is DMSO that provides altered nuclei in more than 
80% of the cells. 
 
Figure 41. Quantification of nuclei lobation of differentiated HL-60 via DAPI assay on fluorescence 





Phagocytic cells as the immune cells have the opportunity to detect pathogens by 
engulfing it. That started a cascade of chemical signaling to define which actions to take. 
Intracellularly, phagocytic cells start a process called respiratory burst in which one of the 
main points is that NAPDH oxidase product reactive oxygen species (ROS). The entire 
coordination of immune responses can then depend on those ROS, but ROS molecules can 
also destroy microbe’s compounds. But an essential role of ROS is to start the regulation of 
pattern recognition receptors, autophagy, NETs or T-cell activation; all those are indirectly 
responsible for eliminating microbes.190 
By using the DCFH-DA assay, we indirectly measure levels of hydrogen peroxide to 
start the oxidation of this probe. We then checked the production of ROS in our 
differentiated-stimulated-HL-60 (fig. 42). The production of ROS was only observed with 
calcitriol, a secondary metabolite of vitamin D has approximately double of activity when 
compared to the positive control, 1mM hydrogen peroxide.  
Figure 42. Quantification of oxidation of 2',7'-dichlorofluorescin-diacetate (DCF-DA) on differentiated HL-60. 




 To explore the differentiation towards neutrophils-like cells, HL-60 cells previously 
stimulated with different agents were labeled with CD11b. A summary is seen in figure 43 on 
which FSC and SSC are defined to find population 1 (P1) as size and granularity to represent 
possible live cells. While the second population (P2) focuses on the fluorescence at 488nm, 
representing the positive cells with the FITC/CD11b marker. This entire figure results from 
measurements on Day 3 of HL-60 differentiation. 
Figure 43A shows the start of gating via finding the measurements of background 
(ethanol control as agent), or so, from the unstained “live” cells. Figure 43B shows ethanol-
HL-60 cells that were still stained cells, but those cells are not neutrophil-differentiated. From 
those controls, we could use HL-60 differentiated cells. 
Figure 43C and D compared DMSOHL-60 cells; however, here the main focus goes to 
the P2 gating. For that, fig. 43D at P2 shows the fluorescent population for 488nm excitation 
and this will then correspond to 63.5 % of the DMSOHL-60 cells. 
Figure 43E shows a table that focuses on Day 6 after HL-60 differentiation. This day 
is important because it correlates that the differentiation of HL-60 can be accomplished for 
the other characterization variables as well. Here we continued the gating strategies to find 
the population of live cells, then find CD11b on live-differentiated HL-60. DMSOHL-60 at day 
6 shows low “live-cells” number (~31%), but from that, 87.4 % of cells are expressing 
CD11b.  
On that note, figure 43D shows results after 3 days of incubation of HL-60 with 
DMSO in which there is 89.2% of live cells (P1), from that 63.5 % are expressing CD11b. 
This could allow the use of DMSOHl-60 on earlier incubation towards functional assays 




Figure 43. Detail of detection and gating of flow cytometric detection of CD11b. A) Non-stained ethanol exposed HL-60 (Day 3). B) Stained ethanol exposed HL-60 (Day 3). 
C) Non-stained DMSO exposed HL-60 (Day 3). D) CD11b-stained DMSO exposed HL-60 (Day 3). E) Summary of CD11b staining and “live” cells with the differentiation 
agents on day 6 of incubation. N= 3 samples per condition on 1 experiment. 
122 
 
Previously, neutrophils were already known to i) phagocytize microbes do its 
elimination into vacuoles or ii) proceed with the release of neutrophilic granules containing 
antimicrobial peptides. But it was uncovered that neutrophils can die via the release of all its 
nuclear content towards the outside of the cell and this release was made into the throw of a 
polymeric mesh containing extracellular DNA (decondensed chromatic) and antimicrobial 
proteins.191 
 Even so, DAPI is a DNA binding dye, Sytox Green has been considered the best 
option for NETosis assay192. With this assays, we investigated if NETs have been produced 
on the differentiated-stimulated HL-60. On figure 44, the qualitative observation of NETs is 
present for the 3 differentiation agents, although either more present or stronger in DMSO or 
calcitriol differentiated HL-60.  
 
Figure 44. Fluorescent micrographs of SYTOX® Green on the detection of neutrophil extracellular traps, among 




 Even though the exact confirmation of NETs is questionable on HL-60 differentiated 
cells, other reports have positively described on its findings193. Besides, NETs have been 
described in essential diseases, while for cystic fibrosis, it may influence the perpetuation of 
excessive inflammation and lung injury194. 
The yellow arrows on fig. 44 point out the presence of cells with traps coming out of 
their nuclear content, representing NETs, while other cells (as the ones from ATRAHL-60 
cells) are positively stained for DAPI and Sytox Green, meaning, these represent cells which 
could potentially present NETs, but contained ones, not yet released. We did not proceed 
with NETs quantification, but importantly we confirmed the presence of these structures in 
CalcitriolHL-60 and DMSOHL60 cells. 
3.2. Neutrophil hitchhiking by Bovine serum albumin (BSA) particles 
 We reproduced the BSA particles179 with slight modification towards the cross-linking 
of albumin with glutaraldehyde. Normally BSA particles tend to form aggregates but 
glutaraldehyde helped on the maintenance of particle morphology. On fig. 45, the 
morphology and physicochemical characteristics of BSA particles are demonstrated from the 






Figure 45. Scanning electron micrographs of BSA liposomes and characterization by size and polydispersity 
index. N =1 independent experiment. 
 
After particle production and checking of its stability, we measured the content of 
albumin into the particles via the BCA assay. That allowed us to define the concentration of 
the particle suspension based on the BSA content in µg/mL. 
This uptake study was only performed on DMSOHL-60 differentiated cells and we used 
two concentrations of particle suspension in order to initially characterized if particle density 
would alter the particle uptake. 
BSA particles were previously stained with rhodamine and then incubated with 
DMSO-differentiated cells. Those cells were previously differentiated and stained for CD11b 
as a phagocytic cell surface marker. 
CD11b/DMSO+HL-60 cells with 10 or 135 µg/mL BSA particles for 2 hours in HL-60 cell 
media. On fig. 46, we observe the results of particle uptake after 2 hours of incubation in 




Figure 46. Neutrophil hitchhiking by Bovine serum albumin (BSA) liposomes. After using diameter and 
granularity to define P1, from those cells, we gated for FITC/CD11b fluorescence (P2), and from this population 
we looked for a population that is also stained by rhodamine (membrane-bound or intracellular). Application of 
10 (A) and 135 (B) µg/mL of BSA liposomes was checked on this uptake study on DMSO-differentiated 





After gating for “live” cells, CD11b positive cells, we defined a population positively 
stained for rhodamine (P3) and in figure 46A for 10 µg/mL and 46B for 135 µg/mL of BSA 
particles. The table shows that 100% of the particles were uptaken or associated with the 
cells. 
  To check the results from flow cytometry, we used CLSM to observe BSA particles 
interacting with the HL-60. We could not find BSA particles using a lower concentration of 
10 µg/mL. With the confocal, we observed the membrane staining for CD11b/FITC 
(fig.47A), while BSA nanoparticles can be seen associated with the CD11b/DMSO+HL-60 cells 
but not defined if uptaken intracellularly. 
 
Figure 47. Neutrophil hitchhiking by Bovine serum albumin (BSA) liposomes. A) Confocal micrographs of the 
investigation of DMSO-differentiated CD11b+HL-60 cells. B) BSA nanoparticle uptake by DMSO-differentiated 
CD11b+HL-60 cells after 2 hours of administration. C) Cross-section of DMSO-differentiated CD11b+HL-60 cells 




 One of the main features of neutrophils is that these are mature cells with lobated 
nuclei, instead of ovoid ones. This transition is also observed in regular granulopoiesis, and 
the nuclei of cells, including HL-60, have already been analyzed after exposure, for instance, 
of retinoid acid195.  
Exposure to all-trans retinoic acid (ATRA) provokes arrest on cell cycle and myeloid 
differentiation, while other agents, as calcitriol can provide a monocytic differentiation196. 
For chemicals as ATRA, HL-60 has already defined mechanisms as a specific retinoic acid 
receptor (RAR) or regulation via microRNAs197. Our testing of agents of differentiation 
clarified the role of DMSO but demonstrated the issues with viability. 
In the activation of neutrophils, the production of intracellular reactive oxygen species 
(ROS) (located in the phagosome) is one of the main strategies to kill bacteria, and ROS 
alters H2O2 to be the source of myeloperoxidase to generate other ROS, including 
hypochlorous acid to fight against bacterial growth198. So the fusion of granules forming the 
phagosome and production is ROS is one of the markers for a neutrophil model.  
Our results show two assays for oxidative stress. For the NBT assay, 40% of the cells 
differentiated with DMSO presented formazan granules that can only be formed by intact 
oxidative cell machinery of a mature phagocytic cell. Another indication of the neutrophil 
commitment of the HL-60 is via the oxidation of DCDH probe.  
Our results show that exposure of HL-60 cells to calcitriol show oxidation of 175% 
when compared to the positive control of H2O2. For DMSO exposed cells, the release was 
only 15%, which questions the functionality of this cell line for this specific function. But, at 
the same time, it asks us the importance of this oxidation for microbe elimination and towards 
a balanced control against lung injury. 
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If neutrophils reach the target (bacteria) to promote phagocytosis and killing, its 
machinery towards migration needs activation.  
This migration takes place when β2-integrins are activated via Mac-1 that is dependent 
on the surface markers CD11/CD18199. HL-60 activated by retinoic acid or DMSO can use 
Mac-1 and extracellular regulated kinases (ERK1/2) across the lung epithelium, as 
demonstrated in Calu-3 epithelia200. The role of epithelia is not passive towards the approach 
from neutrophil migration as on the intestinal epithelia there are specific fucosylated 
proteoglycans that bind CD11/CD18201. 
Our results show it is possible to find CD11b on differentiated HL-60, but mostly on 
DMSO-exposed cells and not on cell exposed with the other differentiation agents. This starts 
to confirm that HL-60 could be used as neutrophil-like cells when DMSO is the leading 
agent. 
 The last functional assay is a dramatic format of cell death called NETosis, as 
neutrophils can decide to extrude a meshwork of DNA/chromatin fibers that are decorated 
with antimicrobial proteins as elastase, cathepsin G and myeloperoxidase; these are the 
neutrophil extracellular traps (NETs). The extrusion of these fibers produces a trap 
mechanism to immobilize and kill pathogens.202  
Although it has been described that HL-60 does not provide NET after differentiation 
with DMSO or ATRA against S. aureus203. Our results after PMA stimulation show an early 
indication of extracellular DNA resembling decondensed chromatin as mesh structures 
resembling NETs. 
If further confirmed (compared to primary neutrophils) that our HL-60 differentiated 
cells present NETS, it can in the future elucidate two things: i) how NETs can be formed and 
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what its composition in primary to cell lines of neutrophils and ii) how the NETosis can be 
useful to release encapsulated strategies inside the neutrophils, as nanoparticle formulations. 
Using the 3 agents for differentiation of HL-60, we contemplate that HL-60 does not 
comprise all neutrophil functionality with one specific differentiated cell. However, it can 
have NAPDH machinery to be activated, expresse phagocytic cell surface marker, show 
neutrophil-like nuclei lobation. All these characteristics after exposure to DMSO. 
Even though cell viability decrease with DMSO expose, we can adapt this towards 
that fact that specific mechanisms of death of HL-60 neutrophils can be useful for  
i) The release drugs or regulated expression of antimicrobial proteins on NETs 
and  
ii) the launch of cytoplasmatic content can release particles if these formulations 
are stable inside the cells. 
 Chu et al179 has shown that BSA particles can be stable inside primary neutrophils and 
hitchhike within these cells using their migratory potential to reach inflamed or infected sites, 
crossing biological barriers to overcome the tissue.  
On DMSO-differentiated CD11b+HL-60, our preliminary results demonstrated cell 
uptake; compaction around the cell nuclei and degree of BSA release, plus aggregation, must 
be assessed in future experiments. Further investigation should be performed on primary 
neutrophils, with specific controls of non-differentiation and with another possible particle 




 HL-60 was used here as a cell model of neutrophils in which its potential to replace 
their functionality could be the option to overcome the short life-span of primary neutrophils.  
 Chemical signals can be purified and used as strategies to promote differentiation and 
further activation of cell models. For neutrophil-like cells, we used DMSO, ATRA, and 
calcitriol. These agents promote differentiation in different degrees176,178,196. 
 Although no agent can differentiate HL-60 to have the full characteristics of 
neutrophils, some new functions can be mimicked. The use of DMSO can promote activation 
of enzymes to produce ROS; it can alter chromatin composition reflected on the nuclei shape, 
it expresses surface markers as CD11b contributing to cell migration, and it can promote the 
specific cell death in combination with strategies for bacteria-trapping, or so, the NETs.  
 Focusing not on the neutrophil functions, but on its potential to release content upon 
NETosis, the use of BSA particles can facilitate a hitchhike for these particles to use the 
migration and chemical signaling of neutrophils. Our BSA particles were uptaken by DMSO-
differentiated HL-60, and now this cell can be used as a model to investigate the mechanisms 
of particle uptake, the stability of different materials inside neutrophils, and the possibilities 






Chapter 3: Coupling quaternary ammonium surfactants to the surface of liposomes to 






The search for new bactericidal molecules has shaken the scientific world on a wave 
of research focusing on how bacteria protein synthesis or respiration chain can be inhibited. 
However, a related investigation is following the potential of molecules or even other bacteria 
to outcompete adhesion onto the human surfaces.204 
Reports on inhibition of bacteria communication205 or specifically adherent proteins, 
as lectins3, have proposed us the opportunity of using nanotechnology and interface 
chemistry to create active surfaces. Responsive surfaces can be developed to inhibit 
determined bacteria, but also to aim for a broader range of bacteria inhibition, depending on 
the interactions with the outer bacteria membrane206.  
With the fact these surfaces can displace and kill bacteria, we observed the 
predominance of quaternary ammonium surfactants (QAS) as primary modifiers. The 
cationic surfactants are primarily employed as antibacterial ingredients in ophthalmic 
preparations207, mouthwashes208, drug delivery food manufacturing209. One example of QAS 
is cetylpyridinium chloride. This compound has antimicrobial activity but in combination 
with cytotoxicity, known as a skin irritant and restricted human application.210 
Successful reports on avoiding bacterial adherence on surfaces have been achieved 
using polymeric coatings with alkylated polyethyleneimine or chitosan derivatives211. A 
commonly seen strategy is to use cationic charge together with a long hydrophobic chain as a 
leading group of the coating solution. This had worked for surfaces212; however, it could be 
applicable for the fight against bacterial adherence, biofilm formation, and resistance. 
When microorganisms gather in communities and attach on abiotic and living 
surfaces, it is called biofilms. From those communities, the related infections, for instance, in 
the USA, account for the $94 billion/year on healthcare costs and around 500,000 deaths/per 
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year213. An immediate need for new molecules against biofilm specific conditions has 
launched the potential of nanotechnology. Mainly for its modulation of size, high surface-to-
volume and possibility of engineering towards strong affinity to bacteria214. Besides the 
feasibility of antibiotic encapsulation into nanoparticles, we can also explore for treating 
bacterial infection with nanomaterials with inherent antimicrobial characteristics215. 
QAS has self-assembly property and soyaethyl morpholinium ethosulfate (SME) 
nanoparticles have recently been proved to eradicate S. aureus and MRSA while penetrating 
bacteria and inducing oxidative stress. Nonetheless, the use of SME-whole micelles mediates 
50% cytotoxicity with only 10 µg/mL210.  
Instead of using QAS on surfaces or as free compounds, we want to functionalize the 
surface of nanoparticles (liposomes) to deliver anti-adherence formulation compatible with 
human epithelia, while the search for new antibacterial cationic surfactants can resolve the 
drawbacks of the currently used surfactants. 
The (11-Mercaptoundecyl)-N,N,N-trimethylammonium bromide (MTAB) is a 
quaternary ammonium surfactant that has been used on surface functionalizations of gold 
particles216, and its derivate Cetrimonium bromide (CTAB) onto gold nanorods is already 
known for antibacterial properties217, a difference that is related just to number of aliphatic 
chains. Choi et al.218 used MTAB to create surfaces with gold particles that can tune in its 
antibacterial activity via electrical stimulations, so its influence on bacteria is being studied 
with positive feedback. 
Our focus is that the integration of MTAB onto liposomes will be easy to produce, 
transfer the properties of QAS as anti-adherence activity and in a less cytotoxic fashion; 
providing the opportunity to use future drugs encapsulation that comprises a combination 
therapy for the remaining non-adherent bacteria. 
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2. Material and methods 
2.1. Preparation of Liposome 
Liposomes were prepared by extrusion procedure using polycarbonate filters (100 nm 
pore size diameter) and were composed of sphingomyelin (Avanti Polar Lipids Inc. 
Alabaster, AL, USA)  and cholesterol (Sigma-Aldrich (Milano, Italy). (1:1mol/mol), 
containing 2.5 mol% of 1,2-stearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide (-
poly(ethylene glycol)-2000)](mal-PEG-PE; Avanti Polar Lipids Inc. Alabaster, AL, USA) for 
further surface functionalization with cationic amino group. Briefly, lipids were mixed in 
chloroform/methanol (2:1, vol/vol) and dried under a gentle stream of nitrogen followed by a 
vacuum pump for 30 minutes to remove traces of organic solvent. The resulting lipid film 
was rehydrated in phosphate-buffered saline (PBS, -Aldrich (Milano, Italy)), vortexed, and 
then extruded (LipexBiomembranes, Vancouver, BC) 10 times at 65°C through a stack of 
two polycarbonate filters (Millipore Corp., Bedford, MA; 100-nm pore size diameter) under 
20 bar nitrogen pressure219. Phospholipid recovery after extrusion was determined by a 
phosphorous assay using the method of Stewart220. This formulation is quoted here as 
“LipoBlank”. 
2.2. Preparation of Liposomes functionalized with a cationic amino group (Lipo-MTAB) 
(11-Mercaptoundecyl)-N,N, N-trimethylammonium bromide (MTAB) was added to 
the LipoBlank dispersion in PBS to give a final cationic amino-to-liposome molar ratio of 2:1 
in the incubation mixture and incubated overnight at room temperature to form a thioether 
bond with mal-PEG-PE. Functionalized liposomes were separated from unbound cationic 
amino linker by dialysis against MilliQ water, using a dialysis membrane MWCO= 12-14 
KDa  (Medical International Ltd, London, UK) at 4°C for 2 days. This formulation is quoted 
here as “LipoMTAB.” 
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2.3. Physico-chemical characterization of LipoMTAB Dynamic Light Scattering 
Liposomes size and polydispersity index (PDI) were obtained using a ZetaPlus 
particle sizer (Brookhaven Instruments Corporation, Holtsville, NY, U.S.A.) at 25 °C in PBS. 
Size and PDI were obtained from the intensity autocorrelation function of the light scattered 
using a 652 nm laser beam at a fixed angle of 90°. The correlation function was analyzed 
through two cumulant expansion. Size and PDI measurements were performed in PBS for at 
least 1 month. ζ-potential analysis (Brookhaven Instruments Corporation, Holtsville, NY, 
U.S.A.) was performed under an electrical field of 29.7 V/cm. Standard deviations were 
calculated from at least three independent measurements. 
2.4. Nuclear Magnetic Resonance (NMR) 
All the NMR 1H experiments were carried out on a Bruker Avance I 600 
spectrometer, (Bruker Italia Srl, 1H base frequency = 600 MHz) equipped with a 
superconducting Ultrashield Plus magnet of 14.1 Tesla, using a 5-mm BBI reverse 
broadband probe. Lipo-Blank (5 mg) and Lipo-MTAB (5 mg) were suspended in 700 µl of 
D2O and introduced in 5mm NMR high-performance tubes for NMR analysis. 
1H spectra 
were acquired, for about an hour, at 30 °C, not spinning, with and without the presaturation of 
the residual H2O signal (zgpr Bruker sequence), using following parameters: spectral width 
(sw) = 7200 Hz, acquisition time (at) = 2.28 s, number of data points in t2 (TD) = 32k, 
relaxation delay (d1) = 5 s and number of scans (ns) = 400. 
2.5. Bacterial cultivation 
Escherichia coli DH5α was used for the microbiological work. After overnight 
incubation (18h) of a single colony in Luria-Bertani broth (Sigma-Aldrich, Germany), the 




The same medium was used for biofilm growth, together with PBS. Biofilm was 
grown by adding 2.107 bacterial cells inside a 12-well microplate (when needed bacteria was 
grown on uncoated glass coverslips 12mm). These plates were incubated at 37oC for 18 hours 
without shaking. 
2.6. Monitoring of bacterial growth by Minimal inhibitory concentration (MIC) assay 
Using 96-well plates, liposome suspension and free MTAB solution, after 2-fold serial 
dilutions, were incubated for 20 hours with E. coli DH5α (107 CFU/mL). Bacterial growth 
was monitored via OD600, using a spectrophotometer. The percentage of inhibition was 
calculated comparing wells with LB medium only. 
2.7. Bactericidal activity by Colony-forming units (CFU) assay 
From the MIC assay, the supernatant of selective concentrations was serially diluted 
in PBS/Tween80 0.05%, drop-plated (3x 20µL drops per dilution) on LB-agar plates and 
incubated for 24 hours at 30°C to determine the CFU. 
2.8. Antiadherence activity by drop diffusion on agar 
Modified from Balouiri et al.221, we prepared LB-agar plates and spreading 100 µL of 
0.2 OD E. coli DH5α. The plates were then dried under the bench flow for 30 minutes. Using 
liposomes and free MTAB solutions, we placed 20 µL drops on the inoculated agar surface 
and let it dry under the bench flow for 30 minutes. Plates were then incubated at 37 °C for 24 
h. The anti-adherence activity was expressed as the mean of the diameter of inhibition halos 
(mm) produced by the formulations. 
2.9. E. coli DH5α biofilm on glass coverslips for SEM and membrane assay 
Using 24-well plates, 250 µL of liposome suspension or free MTAB or controls (PBS 
and LB) were placed on top of sterilized glass coverslips of 12mm and 15 µL of E. coli DH5α 
suspension (107 CFU) was added to the wells. Plates were incubated at 37°C for 72 hours. 
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Wells were PBS-washed (500µL) and supernatant with non-adherent bacteria was collected 
(with care not to touch the coverslips), while adherent bacteria on coverslips were fixed with 
500µL of 3% paraformaldehyde (PFA; Electron Microscopy, PA, USA) for 1 hour.  
2.10. Membrane disruption assay by propidium iodide uptake 
Modified from Cho et al.222, from the biofilm assay, we collect its supernatant 
containing bacteria and then incubated 1µl of 1.5mM propidium iodide (Sigma, Germany) as 
an indicator of membrane disruption for 2 hours and centrifuged at 14000 RPM for 10 
minutes, resuspending the pellets on PBS. Using black glass-bottom 96-well plates (Greiner 
BioOne, Germany), we added 100 µL supernatant containing stained bacteria per well and 
determine fluorescence through Fluorimeter (Excitation 400/Emission 460nm; TECAN 
Infinite M200Pro, Austria).  
2.11. Evaluation of Liposomes biocompatibility via MTT and lactate dehydrogenase 
(LDH) assays on A549 cells 
An adenocarcinoma human alveolar basal epithelial cells (A549 cells; No. ACC 107, 
DSMZ GmbH, Braunschweig, Germany) was grown in complete cell culture medium (RPMI 
1640; PAA Laboratories GmbH, Pasching, Austria) with 10% FCS and used as model cell 
line to test human cell viability. Cells were passaged with trypsin–EDTA and seeded (20 000 
cells per well in 200 µL) on 96-well plates (Greiner, Germany). Liposomes and free MTAB 
were diluted with cell medium (RPMI + 10% FCS) and incubated on the cells for 20 hours. 
The supernatant of cells exposed and unexposed to liposomes was placed in a new 96-
well plate and centrifuged (5000 RPM for 10 minutes), then 100 µL of supernatant was 
separated for LDH assay (Roche Cytotoxicity LDH kit, Germany). LDH kit mix was 
incubated with the supernatants for 5 minutes in the dark at room temperature, according to 
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manufacturer instructions. The absorbance was read by a Tecan microplate reader (Germany) 
at 492 nm. 
Plates with cells were incubated with MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] stock solution (0.5 µg/mL)223 and placed at 37°C for 4 hours. 
After removing the MTT solution, the formazan crystals were resuspended with DMSO 
(100%) for 30 minutes. The absorbance was measured with a spectrophotometer at a 
wavelength of 550 nm. 
Both MTT and LDH were calculated in reference to negative (medium only, 0% 
cytotoxicity) and positive controls (1% Triton-X100, ICN, Eschwege, Germany, positive 
control, 100% of cytotoxicity). 
2.12. Scanning Electron Microscopy (SEM) for liposome and bacteria morphology 
From the biofilm assay, PFA-fixed coverslips dehydrated by an ethanol row with 300 
µl of 30, 40, 50, 60, 70, 80, 90, 96 and 100% for 10 minutes each. Hexamethyldisilazane 
(HDMS; Sigma, Germany) 100% was incubated on wells for 20 minutes then coverslips were 
left to dry overnight under the fume hood. Coverslips were then placed on top of a carbon 
disc and gold-sputtered. Visualization of samples was performed via SEM (copper grid with 
applied liposomes were then placed onto a carbon disc and gold-sputtered). 
3. Results  
3.1. Production and characterization of LipoMTAB 
LipoBlank and LipoMTAB were prepared as described above. Both liposomal 
formulations were characterized by DLS and ζ-potential devices. Lipo and LipoMTAB 
showed a size of 147.8 ± 1.6 nm and 160.8 ± 3.5 nm, respectively and were monodispersed 
(polydispersion index, PDI < 1) (fig. 48B). The liposomes size increased after 
functionalization with MTAB. Also, the ζ-potential value increase from -31.8 ± 5.8 
(LipoBlank) to -20.6 ± 2.6 (LipoMTAB) suggesting the successful liposomes 
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functionalization. Both liposomal preparations maintained a constant size, PDI and ζ-
potential values for at least 1 month, (Fig. 48B). Scanning electron micrographs (fig. 48C) 
showed that both nanoparticle formulations appeared as spherical vesicles and uniform, 
mostly for LipoMTAB that has an additional step of purification via dialysis. 
From a comparison of NMR spectra of Lipo-Blank and Lipo-MTAB in figure 49A 
it is possible to discriminate the signals of (CH3)-N+- (d) at 3.1 ppm and the signals of 
CH2-N- between 3.1 and 3.3 ppm (c), at 2.7 ppm the signal of CH2-S- (a) and between 
1.00 and 2.00 ppm the signals of aliphatic chain of the linker (b). Also, in the 
magnification of the spectra (figure 449D) in the range between 5.80-6.00 a single peak 
attributable to the maleimide signal is present just in the LipoBlank (*) and disappears in 
the Lipo-MTAB sample. Notable, as the difference between magnification of Spectra 3.b, 









Figure 48. Physico-chemical and morphological characterization of liposomes. A) Scheme of liposome production via thiol-maleimide reaction: LipoBlank composed of 
sphingomyelin-cholesterol-DSPE-maleimide with (1) (11-mercaptoundecyl)-N,N,N-trimethylammonium bromide. B) Liposome size over time, measured by DLS. C) 
Stability via size, zeta potential values of liposomes over time assessed by DLS equipped with zeta-pals analyzer and polydispersity index (PDI) of liposomes, measured by 
DLS. All these data are referred to liposomes stored during storage in PBS at 4°C (n=3); C) Scanning electron micrographs of LipoBlank and LipoMTAB (n= 3 micrographs 





Figure 49. Surface characterization of liposomes via NMR. A) Spectra with H2O presaturation; B) 
Magnification of spectra between 5.80 and 6.00 ppm – differences between Lipo-Blank with maleimide 




3.2. LipoMTAB as a formulation against the adherence of E. coli DH5α 
In figure 50A, a representative image relative to the formation of halos, or zones-
of-inhibition, obtained after a 16h of incubation is reported. The results indicate that the 
LipoMTAB (1.8 and 3.6 µmol of lipids, corresponding to 33.8 and 67.5 µg/mL of 
attached MTAB), as the free MTAB (25-200 µg/mL), present well-defined boundaries on 
halos, independent on the presence of the liposomes per se.  From the comparison of the 
results reported in fig. 50B, we can observe that LipoMTAB displayed an average halo-
of-inhibition of 1 cm in diameter at a concentration that corresponds to 33.8 µg/mL of 
attached MTAB, while free MTAB gave halos with the same dimensions only when used 













Figure 50. Liposome activity as bacterial anti-adherence formulation. A) Halo formation during the growth of E. 
coli DH5α on agar plates: Free and liposome-attached MTAB are the only samples where there is halo 
formation, showing attached MTAB has maintained its biological activity. Diameters of halos (3 halos per 
condition per experiment) during the drop diffusion assay of LipoMTAB (B) and free MTAB (C): the amount of 
MTAB and the halo formation is compared on free MTAB (50µg/mL) and on LipoMTAB (67.5 µg/mL of 




3.3. Liposomal formulation did not inhibit bacterial growth or survival  
The antibacterial activity of free MTAB (range of 4-1000 µg/mL) was evaluated 
on E. coli. Growth inhibition was observed with MTAB in a range of 4-1000 µg/mL 
(Figure 51A). However, no antibacterial effect could be seen with the formulations 
(LipoBlank or LipoMTAB, in a range of 0.1-67.5 µg/mL of attached-MTAB) (data not 
shown).  
The focus on bactericidal activity was approached with the colony-forming unit 
assay. In this assay, we focused on the supernatant fraction of the samples, in which we 
determined whether bactericidal effects would derive from leachates, instead of a surface-
based inhibition, where the liposomes would be deposited. The surface will be further 
discussed in the next section, focusing on electron microscopy imaging.  
Fig. 51B shows E.coli survival, focusing on the liposomal particles and controls 
(positive Colistin and negative, PBS no drug). Compared to PBS control, only Colistin 
had bactericidal effects by 50% and free MTAB provided no counted colonies during the 
experiment (data not are shown). LipoBlank and LipoMTAB do not possess a bactericidal 
effect derived from leachates; however, as seen in Fig. 43B, there is also no inhibition of 









Figure 51. Influence of MTAB on E coli growth and survival. A) Minimal inhibitory concentration (MIC) 
follows changes in the turbidity of bacterial culture over 24h; only MTAB from 31-1000 µg/mL can provide 
inhibition (nor LipoBlank or LipoMTAB, at different concentrations, had inhibitory activity). B) Colony-
forming units assay results from bacterial proliferation on agar; comparing Liposomes to no treatment and 







3.4. Liposomal formulation rescue cytotoxicity of MTAB onto lung epithelial cells 
The advantages of bacteria inhibition of free MTAB is hampered by its cytotoxicity. 
Covalent coupling of MTAB on liposomal surfaces also aims to avoid its cytotoxic effect. To 
validate the effect of MTAB functionalized liposomes compared to free MTAB, LDH and 
MTT assays on A549 cells have been performed. The results in fig. 52 showed that when 
MTAB is attached to the surface of the liposome, there is a 25% reduction in LDH release, 






Figure 52. Viability of A549 lung epithelial cells on liposomal formulations and free MTAB. The detection of 
Lactate dehydrogenase (LDH) occurs during membrane burst with the release of cytoplasmatic content as a 
cytotoxic activity, while Tetrazolium MTT is converted to formazan detection only in live cells as a sign of cell 
metabolic activity. Free MTAB is cytotoxic; however, this can be rescued if MTAB is attached to the surface of 
liposomes (n=3). 
 
3.5. LipoMTAB reduces bacteria coverage and destabilizes bacterial membrane, 
resembling Colistin 
Our liposomal particle brings attached MTAB to a biocompatible formulation, 
focusing on the production of a surface to inhibit bacterial adherence. This surface needs 
further assessment, and SEM was our chosen method. Fig. 53A demonstrates area coverage 
of bacteria growth, and on a qualitative assessment, we observe lower coverage on samples 
treated with Colistin and LipoMTAB, while LipoBlank shows increased coverage when 
compared to the control without treatment.  
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A second evaluation was provided by selected images of individual bacteria exposed 
to different treatments. SEM allows observing morphological alterations bacteria at high 
resolution. Zoomed details of Fig. 53A provides the main example of modifications as 
membrane blebbing caused by exposure to high doses of Colistin (0.1 mg/mL; 4 times higher 
than the MIC224). Micrographs from the surface where E. coli was treated with LipoMTAB 
show indentations producing a rough surface on bacteria that possibly induce the release of 
cytoplasmatic content (pointed by the black arrow on Fig. 53A). 
From the shown bacteria during SEM, we assessed membrane stability on the 
remaining E. coli, since CFU was not able to define culturable differences. Fig. 53B shows 
results on the use of propidium iodide as an indicator of membrane impairment212,225. Via 
membrane damage, propidium iodide enters the cells, and its fluorescence can be detected. 
LipoBlank samples do not show fluorescence, and, in comparison to the control, this 
indicates no membrane damage. Using 0.1mg/mL Colistin and control of bacteria damage, 
we found that the treatment with LipoMTAB provides membrane impairment of 74% when 









Figure 53. Liposome activity on E coli surface growth and 
bacterial membrane. A) Micrographs of liposomes, Colistin and 
control with selected views from bacteria membrane. (n=3 
images per sample of 3 experiments). B) Fluorescence of 




The use of QAS as anti-adherence compounds have been extensively studied in the 
last years. One of the main obstacles in their application as anti-biofilm agents in the human 
sphere is due to the cytotoxicity they usually carry out. To overcome this issue, we exploited 
liposomes to obtain a biocompatible anti-adherence formulation of QAS. The (11-
mercaptoundecyl)-N,N, N-trimethylammonium bromide (MTAB) was chosen as QAS for its 
molecular structure: while its reaction and final product are shown in Figure 1. Although it 
has commonly been assumed that the hydrophobic chain plays a pivotal role in the surfactant 
antimicrobial properties, it was also demonstrated that the head group is essential to perform 
the biological activity. In this context, the MTAB positive charged head group strongly 
enhances the interaction with the negatively charged bacterial membrane. Moreover, the 
counterion is also involved in exerting antimicrobial activity. It was proven that the bromide 
counterion is more effective when compared to the others226. 
It was proposed that a “phospholipid sponge effect” explains the results of specific 
adhesion from bacterial anionic phospholipids onto hydrophobic surfaces produced by 
quaternary ammonium groups227. On the development of microbe-killing polymers with 
QAS, it is shown that it can be achieved via non-releasing surfaces. More importantly, it 
is now being acknowledged that the use of surface-attached QAS develops a mechanism 
that can enlist negatively charged phospholipids from the bacterial cell wall and seize 
those within the matrix, in our case, of liposomes.228 
Our hypothesis is that surface-bound MTAB onto liposomes can exploit the 
phospholipid sponge effect, in the account that MTAB is a QAS.  
With the successful production of functionalized liposomes, we, therefore, 
assessed specific adherence of bacterial colonization. We decided to spread the planktonic 
E. coli on agar surfaces in a variation of the Kirby-Bauer disk diffusion susceptibility 
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test229, using drops of treatment solution/suspension, instead of the known antibiotic 
disks. Although this kind of assay does not comprise bacterial killing, it still allows us, to 
mimic a field of action in which the influences on bacteria are dependent on surface 
interactions. 
Thus, the surface covered by bacteria was challenged with free MTAB at different 
concentrations and liposomes with or without MTAB surface functionalization. As 
MTAB is known to inhibit adherence, we used this assay as the primary screening point, 
to achieve an anti-adherence formulation regarding the dose-dependency of the attached 
MTAB liposome.   
The data from Fig. 42 suggests that the efficacy of MTAB is enhanced when the 
molecule is exposed on the nanoparticle surface rather than free in solution. These results 
are the first proof of the possibility to transfer the anti-adherence bacterial activity of 
MTAB onto a liposomal formulation by attaching the molecule on the nanoparticle 
surface avoiding encapsulation, a method that probably makes more effective its activity.  
This shown anti-adherence activity must be further explored, and the first expected 
question is the release of MTAB, either from the breakdown of the liposomes or from a 
non-sufficient purification of the formulation after the MTAB functionalization.  Despite 
no bactericidal effects of the liposomal formulations, this data from the drop diffusion on 
agar shows that the role of the formulations will focus on the surface of growth. 
On that note, liposome fluidity influences how these particles interact with 
bacteria and, depending on the bacteria, also on its phospholipid composition, e.g., 91% 
of phosphatidylethanolamine on the outer membrane of E. coli230. Our formulations were 
analyzed on a 24 h of interaction with E. coli, and this time point, together with bacteria 
proliferation and consequent lower pH, is expected to promote liposome fusion to be 
delivered to the surface (in our case of the glass coverslips) or bacterial 
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membrane/biofilm surface. From imaging the washed surface of the sample by SEM, we 
concluded the remaining small number of bacteria could not differentiate the effects of 
free versus attached-MTAB via the CFU assay. 
If its action on bacteria was shown, we checked the safety of the formulation. In an 
initial assessment, we saw that the advantage of using covalent linked Lipo-MTAB is the 
formation of stable thioether linkage along with the functionalization to the phospholipid 
layer. By coupling MTAB to the surface of liposomal carriers, we could reduce this 
compound toxicity while improving biological activity against bacteria.231 
Micrographs from the surface where E. coli was treated with LipoMTAB show 
indentations producing a rough surface on bacteria that possibly induce the release of 
cytoplasmatic content 
SEM micrographs showed indentations and more irregular surfaces on bacteria 
with an indication of the opening of membrane barrier. Using propidium iodide as an 
indicator of membrane impairment212,225, we checked for membrane damage, as propidium 
iodide enters the cells, and its fluorescence can be detected. 
The results of LipoMTAB providing membrane impairment of 74% - when compared 




QAS has provided the primary tool to develop surfaces that kill and inhibit bacterial 
adherence. This effect can now be used on the engineering of QAS into a well established, 
and FDA approved nanoparticle formulation that also allows encapsulation of drugs. We used 
liposomes on the usefulness of its fluidity to provide easy encapsulation of drugs, but also on 
fusion to the bacterial membrane. LipoMTAB is quickly produced via a thiol-maleimide 
Michael reaction using a commercial QAS (11-mercaptoundecyl)-N,N,N-
trimethylammonium bromide. This formulation was characterized and shown to be 
homogenous and pharmaceutically stable.  
Using E. coli DH5α, LipoMTAB showed similar results on the inhibition of bacterial 
adherence than its free counterpart, with the advantage of decreasing cytotoxicity of MTAB 
when covalently attached to our liposome. Despite no detectable effect on bacteria growth or 
survival, SEM showed improved antiadhesion properties on washed surfaces, as comparable 
as colistin, while remaining bacteria on LipoMTAB samples were demonstrated to present 
membrane damage as initial insight into the mechanism of action of this formulation. The 
presented study provides facile production of a new formulation that presents an influence on 
bacterial adherence, leading the path for combination therapy against bacterial infection and 
biofilm formation.   
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Chapter 4. General conclusions and future perspectives  
The lung is one of the most critical routes concerning the entering of particles and 
pathogens in the human body and this brings advantages and disadvantages. The benefits 
consist of the possibility to deliver drugs directly on targets that are exposed to the air-
interface of the lung. Furthermore, the inhalation of particles can be used to deliver drugs 
with solubility issues, target problems in different areas of the lung or specific cells and 
crosse specific biological barriers as the bacterial biofilm. 
This dynamic counts with other challenges that alter the physiology and structure of 
the lung. The blockage of the airways is known as bronchiectasis, in which the leading causes 
are related to lung infection, alteration on lung fluid/mucus, or neonatal remodeling. Cystic 
fibrosis counts with all these alterations. As a genetic disease, it brings defects on the CFTR 
channel affecting mostly the lungs, pancreas and gastrointestinal tract. 
For the lungs, CF remodels the airways, decreases the absorption of chloride that 
impairs the transport of water into the cells, alters mucus viscosity that contributes to the 
blocking of airways, facilitates the adherence of bacteria and thereby allowing the transition 
of bacteria from planktonic to biofilm, while inducing excessive inflammation, lung damage 
and alterations of the immune system. 
Passing by these characteristics, the complexity of this disease was attempted to be 
modeled on small animals, and in mice, it can be observed the non-conformity of CFTR or 
EnaC mutations or even simple resolution of infection/inflammation. There are advantages 
from this and other in vivo models, but to provide focus on molecular mechanisms, the use of 
cells is recommended232. 
From direct lung cells to immortalized cell lines, the use of CF cells has started the 
field on the modeling of this disease. Cells as CFBE41o-, intrinsically presenting deletion of 
CFTR via the ΔF508 mutation, bring the potential to understanding epithelial alterations in 
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the presence of disease. When combining cells and pathogens, we increase the complexity of 
the system and get closer to the in vivo situation. Important cells command the immune 
reaction, while others create a biological barrier, and with those, the insight on pathogen 
adaptation and growth is further analyzed. 
This thesis presents a combination of CF epithelia, macrophages, and P. aeruginosa in 
the view of providing a platform to test new antibacterial agents while allowing them to 
investigate host-pathogen interaction. From optimizing cell adaptation to bacterial growth, 
this first step allowed the understanding of how to perform the first co-culture of cells and 
bacteria. A second optimization was required to include the second cell type and then 
promote infection. 
A co-culture of CFBE41o- epithelia, THP-1 macrophages, and P. aeruginosa 
provided the comprehension of cell death facing infection, but also the potential for stability 
among regulation of cell growth, epithelial barrier, and macrophages transmigration. Even 
though we would still require more information on cell interactions, the insights into 
alterations of cell morphology and viability will capture the need to understand how and why 
bacteria develop differently on top of cells versus when bacteria are alone. 
Our model is stable for 24h without infection and 6 hours after the infection with P. 
aeruginosa, bringing an essential window for the investigation on biofilm initiation, cell 
behavior towards the regulation of cell surface markers, stimulation of migration and 
initiation/maintenance of inflammation. This was observed within 3 hours of infection in 
which macrophages cross the transwell membrane and the epithelial layer to reach bacteria. 
However, without treatment, this migration does not avoid the formation of in vitro 
mushroom-shaped biofilms. 
If macrophages are transmigrating, we could observe the immediate (3hpi) uptaking 
of bacteria by those cells when on top of the epithelial layer. This brings opportunities to new 
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strategies to identify mechanisms of macrophage transmigration, of improvement of 
epithelia-macrophage interaction, and on clearing of infection. 
Because these cell dynamics are occurring, we investigated how P. aeruginosa 
adapted its growth on top of the different cell types when compared to the abiotic 
environment as plastic microplates.  
When growth could present differences, the efficacy of known drugs could be 
assessed to alter this infected environment. Tobramycin administration on the different 
conditions was able to control bacterial early growth, but not the formation of biofilm and 
potential pressure for increased expression of resistance genes. Importantly, this drug efficacy 
was shown to be statistically different when comparing bacteria-only surfaces versus bacteria 
on a cellular surface. One log of difference is found on infected double cell co-culture if 
compared to bacteria alone, and this could influence drug potential during the preclinical 
testing of discoveries. 
Associated with infection, inflammation has its production via the release of 
cytokines, and on a panel analysis of uninfected, infected, and infected treated mono and co-
cultures, we observe the proinflammatory potential of sterile interaction in between the cells 
and the stimulation via P. aeruginosa growth. This potential was associated with cytokines 
related to neutrophil recruitment, activation of the inflammasome via NF-қB and the 
regulation of foreign DNA-sensing in cells. Plus, new cytokines are now demonstrated to 
influence infection and tobramycin treatment, focusing on how models that combine key cells 
for disease progression can bring a platform for the control of inflammation. 
This control will not mean the complete extinguishment of cytokine production. An 
important lesson here is that cytokines must be remembered as regulatory signals and its 
network is designed to increase inflammation to fight infection. Most cytokines are molecular 
effectors to initiate bacterial killing. Immunomodulation on anti-inflammation cytokines as 
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IL-10 or proinflammatory as IL-6 and IL-8 will connect the physiological and the excessive 
reaction of the immune system, but also bring the potential of discovery antibodies and 
particles as therapy. 
If the host response was initially characterized, bacteria growth is beyond being a 
regular aggregation. Its formation of communities required communication and this is 
regulated by virulence factors as pyocyanin and pyoverdine. Those molecules regulate the 
Pseudomonas Quinolone System and are in demand for drug testing/delivery platforms233. 
For us, although variation on cell types did not influence the production of these factors, the 
regular release of bacteria that are re-adapting in a live and different substrate is an advantage 
to integrate results on a more complex model, providing simultaneous analysis of cells and 
bacteria. 
This co-culture was successful in integrating macrophages as representative of 
immune cells. Other cells from the innate immunity will provide tools of inflammation 
control and even new technologies on drug delivery. Neutrophils are critical cells on the 
production of antimicrobial peptides and specific trapping for bacteria-killing. These short-
lived cells are challenging to handle, and cell lines as the HL-60 have been considered an 
option. During this thesis, there was a characterization for the differentiation of HL-60 
promyelocytes as neutrophil-like cells. 
By using the early cell death of neutrophils, a new strategy is provided: the use of 
particle to hitchhike activated neutrophils towards the infected site. It was shown that BSA 
particles have this potential, and in combination with HL-60 as a cell model, there is the 
chance to analyze: what are the material (lipids, polymers, etc.) that regulate this uptake and 
what sort of surface chemistry influences this stability inside neutrophil-like cells? Can the 
migration of neutrophils be integrated into the presented co-culture to mimick the CF infected 
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environment and the need for specific delivery drugs and particles? Is the use of drug-loaded 
particles and NETs effective therapy against bacterial infections? 
Once bacteria is installed, the formation of biofilm alters all possibilities of drug 
efficacy and few models present alternatives for testing. The use of particles to protect drug 
stability or targeting is everyday, including the potential to modify the surface of these 
particles. Understanding the use of quaternary ammonium salts as antimicrobial molecules 
bring this use to decorate particles, especially liposomes. With our Sphingomyelin-
Cholesterol-DSPE liposomes decorated with MTAB, E. coli adherence can be inhibited with 
the potential to disrupt the bacterial membrane, rendering potential to avoid biofilm 
formation. There is a need to continue to investigate these particles towards its use on drug-
loading and influence on the growth of other relevant bacteria. 
Finally, the co-culture is now a platform where drug testing is now brought to the 
level of complexity that gathers markers from both cells and bacteria. Future experiments on 
the interaction of cells can provide insights into the increase of antimicrobial molecules on 
lining fluid or its transport to mucus. Mucus needs to be considered here as an additional 
barrier to understanding the regulation of viscosity, propensity for infection and particle 
clearance during the modeling of CF disease. 
Different barriers are created upon the interaction between cells and bacteria. Not only 
drug transport is altered, but the application of nanoformulations for the lower airways should 
be investigated on cell uptake, stimulation of migration and cell morphology and its 
consequent effects from bacterial adaptation. 
As the infected model is stable with all components until 6 hours post-infection, new 
efforts should be considered to prolong this time window, especially on the potential to 
develop mature biofilm and the possibility of drug administration in repeated doses. 
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Drug delivery as a field must look for the needed and complex environment that 
molecules or particles will interact with. It will be then closely-related to cell metabolism and 
physiology. Co-cultures like this provide the substrate, a living substrate that can be 
controlled, but that at first, it must be characterized. 
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3D  three-dimensional 
ALI air-liquid interface 
ATCC American Type Culture Collection 
ATRA all-trans retinoic acid  
BBI Broadband Decoupling Inverse 
BETR  baseline, exacerbation, treatment, recovering 
BSA bovine serum albumin 
cAMP 3',5'-cyclic adenosine monophosphate 
CD cluster of differentiation 
CF Cystic Fibrosis 
CFBE Cystic Fibrosis bronchial epithelia 
CFDA 5-Carboxyfluorescein diacetate 
CFTR cystic fibrosis transmembrane conductance regulator  
CFU colony-forming units 
CLSM Confocal Laser Scanning Microscopy  
cm centimeters 
COPD  Chronic obstructive pulmonary disease 
CTAB cetrimonium bromide  
DAPI 4′,6-diamidino-2-phenylindole 
DCFH-DA 2',7'-dichlorofluorescein-diacetate  
DCs dendritic cells  
DLS Dynamic Light Scattering 
DMSO  dimethylsulfoxide 
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DSMZ Deutsche Sammlung von Mikroorganismen und Zellkulturen  
DSPE-PEG(2000) 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[amino(polyethylene glycol)-2000] 
EDTA Ethylenediaminetetraacetic acid  
ELISA  Enzyme-linked immunosorbent assay  
ENaC epithelial sodium channel 
ERK extracellular regulated kinases  
ESKAPE  Enterococcus, Staphylococcus aureus, Klebsiella species, Acinetobacter 
baumannii, Pseudomonas aeruginosa, Enterobacter 
EVOMepithelial volt ohmmeter  
FDA  United States Food and Drug Administration 
FITC fluorescein isothiocyanate 
fMLP N-Formylmethionyl-leucyl-phenylalanine  
FSC forward scatter 
GFP green fluorescent protein 
GM-CSF Granulocyte-macrophage colony-stimulating factor  
h hours 
HDMS Hexamethyldisilazane  
HIPS Helmholtz-Institute for Pharmaceutical Research Saarland 
HL human leukocyte 
hpi hours post-infection 
HPLC High-performance liquid chromatography 
IFN interferon 
IL interleukin 
IL-1Ra IL-1 receptor antagonist  
IL-1RAcP IL-1 receptor accessory protein  
IL-1RI IL-1 type I receptor 




LAS  Leica Application Suite  
LB  Luria-Bertani 
LDH lactate dehydrogenase 
LPS lipopolysaccharide  
M molar 
MBEC Minimum biofilm eradication concentration 
MBIC Minimum biofilm inhibitory concentration 
MEM  Minimum Essential Media 
mg milligrams 
MHC Major histocompatibility complex 
MIC Minimum inhibitory concentration 
min minutes 
mL milliliters 
MMP  matrix metalloproteinases 
MOI multiplicity of infection 
mRNA  messenger Ribonucleic acid 
MRSA Methicillin-resistant Staphylococcus aureus 
MTAB (11-mercaptoundecyl)-N,N,N-trimethylammonium bromide 
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MWCO molecular weight cut-off 
NADH  oxidized Nicotinamide adenine dinucleotide 
NBT Nitroblue tetrazolium  
NEAA non-essential amino acids  
NET neutrophil extracellular traps 
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NF-қB nuclear factor kappa-light-chain-enhancer of activated B cells  
NK natural-killer 
nM nanomolar 
NMR Nuclear Magnetic Resonance  
OD optical density 
OTUs operational taxonomic units  
PAMPs pathogen-associated molecular patterns 
PAO Pseudomonas aeruginosa  
PBS phosphate-buffered saline 
PDI polydispersity index  
PET  Polyethylene terephthalate 
PFA  paraformaldehyde  
pg picograms 
pH potential hydrogen 
PMA  phorbol 12-myristate 13-acetate 
PMN polymorphonuclear neutrophil  
PPGAS protease peptone glucose ammonium salt 
PQS Pseudomonas quinolone signal  
QAC quaternary ammonium compounds 
QAS quaternary ammonium surfactants 
RAR retinoic acid receptor  
ROS  reactive oxygen species 
RPM rotations per minute 
RPMI Roswell Park Memorial Institute  
RT room temperature  
SD standard deviation 
SEM Scanning Electron Microscopy  
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SME soyaethyl morpholinium ethosulfate  
SSC side scatter 
TEER transepithelial electrical resistance 
TIMP tissue inhibitors of metalloproteinases  
TJ  tight junctions 
TLR Toll-like receptors 
TNF tumor necrosis factor 
tob tobramycin 
TSLP thymic stromal lymphopoietin 
TTSS type III secretion system  
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